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The mismatch repair (MMR) pathway maintains genome stability by repairing mutations 
incorporated in the genome during replication and recombination. While most microorganisms 
tend to have low mutation rates, a higher mutation rate can provide transient adaptive advantage 
to stress conditions by promoting adaptive mutations. Variants of the MMR genes, MLH1 and 
PMS1 from different yeast strains can display an incompatibility that results in a high mutation 
rate. MLH1 and PMS1 function as a heterodimer and the incompatibility is a result of single 
amino acid polymorphism in each protein. The incompatibility provides an adaptive advantage 
under stress but does so at the cost of long-term fitness. I identified 18 baker’s yeast isolates 
from 1011 yeast isolates surveyed that contain the incompatible MLH1-PMS1 genotype in a 
heterozygous state. I tested the mutation rates of two clinical heterozygous diploid isolates, 
YJS5885 and YJS5845, and their spore clones. While both of these isolates were non-mutators, 
their meiotic spore progeny displayed mutation rates that varied over a 340-fold range, and 
MLH1-PMS1 incompatibility was the major driver of high mutation rate. The range in mutation 
rates might be in part because these isolates are heterozygous for several genes that may be 
modifying the mutation rate. My data are consistent with the variance in mutation rate 
contributing to adaptation to stress conditions through the acquisition of beneficial mutations, 
with high mutation rates leading to long-term fitness costs that are buffered by mating, or 
  
eliminated through natural selection. Furthermore, I observed that one of the isolates was 
aneuploid and generated aneuploid spore clones at a high frequency. Aneuploidy also provides a 
transient adaptive advantage under stress conditions. Thus, I obtained evidence for mechanisms 
in clinical yeast isolates that may provide an adaptive advantage in the human body. 
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FOREWORD 
 
The majority of the work described in my thesis is to understand different aspects of 
mismatch repair of DNA and crossing over during meiotic recombination both using an 
evolutionary perspective as well as to gain a mechanistic understanding of these basic cellular 
pathways. 
In Chapter 1, I give an overview of adaptation mechanisms in clinical isolates of baker’s 
yeast. This chapter is an introduction to the thesis and is also going to be submitted as a review. I 
have also included a future directions section based on the introduction and work done in 
Chapter 2. 
In Chapter 2, I present the work on clinical isolates of baker’s yeast bearing 
incompatibilities in the mismatch repair genes MLH1 and PMS1. These isolates were diploids 
and heterozygous for the MLH1-PMS1 incompatibility and I found that upon sporulation they 
generated progeny that had a wide range of mutation rates. MLH1-PMS1 incompatibility was a 
major contributor to high mutation rates. Furthermore, I observed high rates of aneuploidies in 
the isolates and spore clones as well, pointing towards multiple adaptation phenotypes in these 
isolates. The future directions for Chapter 2 are presented as a part of Chapter 1. 
In Chapter 3, I present the work I have done to understand the mechanism of the 
endonuclease, Mlh1-Mlh3 in yeast and mouse and how it functions in the two different cellular 
pathways: mismatch repair and meiotic recombination. Biochemical and genetic analyses of 
separation of function mutants of mlh3 in yeast indicate that protein-protein interactions are key 
to directing Mlh1-Mlh3 in mismatch repair and recombination. The chapter includes the work 
 xvii 
that I performed in two publications: Al-Sweel, Raghavan et al., PLoS Genetics 2017;13(8); 
Toledo, Sun, Brieno-Enriquez, Raghavan et al., PLoS Genet. 2019 In Press. It also includes a 
new protocol for the purification of yeast Mlh1-Mlh3 that I developed to substitute for an older 
protocol that we have since discontinued. 
Chapter 4 includes the future directions for Chapter 3. Here I present my work with 
another meiotic recombination protein, Exo1 to understand how this protein interacts with Mlh1-
Mlh3 and its effect on the endonuclease activity and crossover resolvase function of Mlh1-Mlh3, 
and I suggest future experiments for this project. 
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CHAPTER 1 
 
 
 
Clinical isolates of baker’s yeast provide a model for how pathogenic yeasts adapt to stress. 
  
 
 
 
 
This chapter is going to be submitted as a review with co-authors Chip Aquadro and Eric Alani. 
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Abstract 
 
Recent global outbreaks of drug resistant fungi such as Candida auris are thought to be due at 
least in part to excessive use of antifungal drugs. The baker’s yeast Saccharomyces cerevisiae 
has recently gained importance as an emerging opportunistic fungal pathogen that can cause 
infections in immune-compromised patients. Analyses of over a 1000 S. cerevisiae isolates are 
providing rich resources to better understand how fungi can grow in human environments. A 
large percentage of clinical S. cerevisiae isolates are heterozygous across many nucleotide sites, 
and a significant proportion are of mixed ancestry and/or are aneuploid or polyploid. Such 
features potentially facilitate adaptation to new environments. These observations provide strong 
impetus for expanding genomic and molecular studies on clinical and wild isolates to understand 
the prevalence of genetic diversity and instability generating mechanisms, how they are selected 
for, and how they are maintained.  
  3 
Saccharomyces cerevisiae, a model for studying pathogenic yeast 
Saccharomyces cerevisiae, or baker’s yeast, is a well-studied single-cell model eukaryote used to 
understand a wide-variety of cellular pathways. It is found in many natural environments 
including trees, fruits and soil, is extensively used in industrial fermentation to make bread, beer, 
and wine (e.g.[1, 2]), and has been found in the respiratory, gastrointestinal, and urinary tracts of 
healthy individuals ([3-7], reviewed in [8]). It is not thought to adapt quickly to the changing 
conditions that occur in the human body, and its presence does not normally cause infections 
because it can be cleared by the immune system and does not cross epithelial barriers [3-7]. 
However, recent molecular and genomic analyses of S. cerevisiae natural isolates (see Glossary) 
have identified loci and mechanisms that promote genetic variability and genomic instability, 
and consequently aid in adaptation to stressful environments [8-11]. This review provides an 
overview of genomic processes that can promote adaptation of baker’s yeast to changing 
environments and how such adaptation may lead to virulence in a human host.   
 
S. cerevisiae, an opportunistic pathogen  
Over the past 25 years, a significant effort has been made to collect and characterize S. cerevisiae 
isolated from patients (for examples see [11-17]). It has been designated as an emerging 
opportunistic pathogen that can cause infections in immune compromised patients, and is 
associated with virulence when the epithelial barrier is breached [5, 18]. The association of 
baker’s yeast with human infection has become better recognized due to improved diagnostic 
methods. S. cerevisiae causes roughly 1-4% of severe fungal infections, with Candida albicans 
(~53-58%) and Candida glabrata (~20-23%) causing the majority [19]. There are a few extreme 
cases where S. cerevisiae is the direct cause of mortality, usually by inducing sepsis [19]. 
Baker’s yeast infection is associated with several illnesses including pneumonia, peritonitis, 
esophagitis, and liver abscesses (reviewed in [20]). Furthermore, it can cause infections ranging 
from vaginitis in healthy patients, cutaneous infections, systemic bloodstream infections, and 
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infections of essential organs in immunocompromised and critically ill patients [5, 20-22]. Based 
on these reports, S. cerevisiae is considered a low-virulence human pathogen [8, 22]. 
 
Challenges for baker’s yeast in the human host and clinical environment 
The human body is a stressful growth environment for baker’s yeast due to the presence of high 
temperature, antifungal agents, antimicrobials, and competing commensals and/or infectious 
microbes. These stresses are analogous to what yeast might experience in a wine fermentation 
environment, which is constantly fluctuating [23]. The patient in a clinical setting may thus pose 
a particularly challenging environment compared to yeast growing in a typical environment such 
as the bark of a tree or in a vineyard. Major factors that allow for opportunistic infection by S. 
cerevisiae are impaired host immune response, use of invasive and infected catheters in 
hospitals, antibiotic therapies to treat some infections, and probiotics that S. cerevisiae [20, 21]. 
Thus, it is not a surprise that the majority of infections caused by S. cerevisiae are hospital 
acquired. Apart from being a commensal in patients and health-care workers, it may be acquired 
from other infected patients and may appear in the hospital environment through probiotics and 
other food sources [5, 20-22].  
 
Can human behavior impact adaptation mechanisms? 
Indiscriminate use of antimicrobials is thought to be a leading cause of the generation of multi-
drug resistant bacterial pathogens [24]. Recent work has suggested a similar situation in fungi 
[25, 26]. Excessive use of antifungals in farm animals and crops is thought to be a major source 
of drug-resistant fungi that cause infections. This is exemplified by global outbreaks of Candida 
auris within the last five years [25]. This pathogen is resistant to major antifungal medications 
and causes infections in patients with weak immunity such as critically ill patients, infants and 
patients on immune-suppressive medications. The commensal fungal population is important to 
maintain gut health and promote anti-fungal immunity [26]. However, the use of probiotics, 
especially in immune-compromised patients, is also thought to provide an advantage for specific 
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fungi to grow in a clinical environment. For example, Saccharomyces boulardii, a subtype of S. 
cerevisiae is used in probiotics for the treatment of diarrheal disease such as those caused by 
Clostridium difficile [5, 21]. These live preparations are often consumed at high doses for long 
periods of time and have been associated with invasive S. cerevisiae infections in 
immunosuppressed individuals [5, 21]. 
 
Phenotypes associated with virulence 
Some of the earliest studies analyzing baker’s yeast infections in mammals were performed by 
Clemons et al. [12], who compared the virulence of clinical and non-clinical human isolates by 
injecting them into immune-compromised mice. They found virulence was likely to be a 
dominant trait involving multiple loci [12]. Outlined below and in Table 1.1 are summaries of 
phenotypes that are important for growth in clinical conditions. 
 Antifungal resistance. The most common class of antifungals, azoles, targets enzymes in 
the ergosterol biosynthesis pathway. Ergosterol is the major sterol in the plasma and 
mitochondrial membranes of fungi. It is not present in mammals and is an established target of 
antifungals [27]. Resistance to antifungals can occur through the deletion or overexpression of 
genes that regulate membrane transporters that cause efflux of the drug, or modulate the 
expression of targets in the ergosterol pathway (Table 1.1; [28-32]). For example, in 
experimentally evolved populations (defined as cultures grown in a laboratory condition for a 
large number of generations) of S. cerevisiae, resistance to the antifungal fluconazole resulted 
from mutations in several targets [28]. At low drug concentrations, diploids acquired resistance 
more rapidly than haploids. This advantage was thought to be due to resistance resulting from 
dominant mutations and diploids having twice the number of mutational targets. At high drug 
concentrations, resistance occurred more quickly in haploids due to the acquisition of recessive 
mutations. In experimentally evolved populations of C. albicans, resistance to fluconazole 
resulted from an additional copy of isochromosome 5L, which became fixed in multiple 
independent populations [31]. 
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 High temperature growth. The ability to grow at high temperature aids in virulence of S. 
cerevisiae. Four genes have been linked to high temperature growth in S. cerevisiae: NCS2, 
MKT1, END3 and RHO2 [33, 34]. These, along with other unmapped loci, were identified 
through a targeted backcross mapping strategy and reciprocal hemizygosity analysis [33, 34]. 
 Colony phenotype switching. Many clinical isolates display several colony phenotypes; 
these can include differences in smoothness, color, size and colony border color [13, 35]. 
Clemons et al. [35] observed that clinical isolates showed different colony phenotypes based on 
the media grown in, and such phenotypes were reversible. Colony phenotype switching was 
observed more often in clinical compared to non-clinical isolates [35]. Such a property likely 
facilitates colonizing different parts of the human body that provide different stress conditions 
and nutrient availability. It is also important to note that meiotic progeny of clinical isolates can 
display a wide variety of colony phenotypes in a single growth condition (for example, see [10]). 
 Pseudohyphal growth. In this condition, cells bud and become elongated but the buds do 
not separate, creating chains of cells that can invade the growth substrate [36]. This unipolar 
growth may be important under nutrient deprived conditions to identify food sources. Virulent 
isolates show significantly higher pseudohyphal growth compared to avirulent isolates [37].  
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Table 1.1: Phenotypes observed in fungi grown in clinical environments or conditions. 
 
Phenotype Description 
Antifungal 
resistance 
1. Genes that act in drug efflux pathways. 
 
A. Overexpression of genes in clinical isolates of C. albicans [32].  
i. CDR1 and CDR2: ABC (ATP-binding cassette) transporters  
ii. MDR1: Regulates intracellular protein transport 
 
B. Experimentally evolved S. cerevisiae [28]. 
i. PDR1: Mutations in this transcription factor cause 
overexpression of PDR5 and SNQ2  
ii. PDR3: Mutations in this transcriptional activator alter 
expression of ABC transporters. 
 
2.   Overexpression of genes observed in experimentally evolved  
      S. cerevisiae treated with fluconazole or amphotericin B.   
 
Overexpression of the following genes was reported to cause 
increased drug efflux [29]: ICT1 (phosphatidic acid biosynthesis), 
YOR1 (ABC transporter), GRE2 (catabolism of some sugars), 
PDR16 (lipid synthesis), YGR035C and YPL088W (unknown). 
 
3.   Modulation of expression of ergosterol biosynthesis pathway     
      genes in experimentally evolved S. cerevisiae [28, 30]. 
 
A. Loss of function mutation in ERG3 causes overexpression of 
ERG11 which causes resistance to fluconazole 
B. Loss of function of ERG6 causes resistance to fluconazole 
 
4.   Aneuploidy of isochromosome 5L and trisomy of  
      chromosome 7 in experimental evolution of C. albicans [31].  
 
High temperature 
growth 
Mutations in NCS2, MKT1, END3 and RHO2 in S. cerevisiae [33, 34].  
Colony phenotype 
switching 
Linked to clinical isolates of S. cerevisiae [13, 35]. 
Pseudohyphal 
growth 
Linked to clinical isolates of S. cerevisiae [37]. 
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Genetic mechanisms that contribute to baker’s yeast virulence 
Studies on natural and clinical isolates have identified different factors that aid in the adaptation 
of baker’s yeast to stress environments (Figure 1.1). Many of these factors have been associated 
with exposure to human associated environments. These include: 1. Multi-site heterozygosity, 
which offers a wider exploration of phenotypes in the progeny of an organism. 2. Mosaicism, 
created when multiple isolates in a single environment outcross to create a novel isolate. 3. High 
mutation rates, which provide a source of mutations that can accelerate adaptation. 4. 
Aneuploidy, or change in the number of one or more chromosomes, provides a transient 
adaptive mechanism. 5. Polyploidy, which is also observed in natural isolates, and can generate 
genome instability and variability associated with rapid adaptation. 
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Figure 1.1. Factors aiding in adaptation of S. cerevisiae clinical isolates. Several interrelated 
factors that lead to genetic variation and genomic instability help in yeast adaptation to clinical 
environments. Heterozygosity and mosaicism of isolates results in spore clones accessing larger 
genotypic and phenotypic space and also give rise to new combinations of genes and alleles, 
which aid in adaptation to new environments. The allelic variation and hybrid incompatibility 
resulting from heterozygosity and mosaicism can also cause variation in mutation rates. 
Aneuploidy and high mutation rates provide a transient advantage in sudden stress conditions 
and aneuploidy generates huge phenotypic variations which may lead to high mutation rates. 
Polyploids, show genome instability phenotypes that include an increase in the frequencies of 
chromosome mis-segregation causing aneuploidies, a higher generation of mutations, and also 
provides a larger genotypic and phenotypic space, consequently displaying rapid adaptation [38]. 
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1. Multi-site heterozygosity 
Multi-site heterozygosity is defined as the presence of allelic variation at multiple loci in the 
same yeast strain. In the 1011 S. cerevisiae genome project [9], heterozygous isolates contained 
2,000-78,000 single nucleotide sites that were heterozygous. More specifically, 63% of 794 
diploid natural isolates and 49 of 107 clinical isolates were heterozygous at multiple nucleotide 
positions (Table 1.2). In general, higher levels of heterozygosity were associated with isolates 
recovered from human-associated environments [9, 11, 15, 39]. A simple explanation for the 
above findings is that actions by humans, such as consuming yeast and culturing them for beer 
and wine, increases the possibility of outcrossing by increasing stress conditions and providing 
proximity to other isolates [15, 39]. Thus, by inference, outcrossing between different isolates 
would lead to multi-site heterozygosity. With respect to clinical isolates, Muller and McCusker 
[39] showed that levels of heterozygosity at 12 microsatellite markers were higher in clinical 
compared to non-clinical isolates, and Magwene et al. [15] showed in a small sample that 
clinical isolates have a larger proportion of heterozygosity in their genomes compared to non-
clinical isolates. However, it is important to note that Peter et al. [9] found a wide variation of 
heterozygosity in the 49 clinical isolates. 
How is heterozygosity generated? Baker’s yeast can reproduce asexually as well as enter 
meiosis infrequently for sexual reproduction to generate haploid spores. Once spores are formed, 
S. cerevisiae haploid cells have the potential to switch mating type (if homothallic) and 
autodiploidize to create a homozygous diploid or mate with other haploid progeny in the 
vicinity, termed as outcrossing. Heterozygosity at multiple loci can result by recent outcrossing 
events or from the accumulation of mutations during vegetative growth. Outcrossing in baker’s 
yeast, which depends on environment and proximity to other isolates, has been estimated to 
occur between 1 in 100, to 1 in 50,000 vegetative divisions [23, 40], with high rates observed in 
the gut of social wasps [41]. A closely related yeast, Saccharomyces paradoxus, is unable to 
survive in the gut of social wasps, but conditions in the gut favor their sporulation and 
germination and most importantly, mating with S. cerevisiae to form hybrids that can survive 
  11 
[41]. Mixed ancestry from two or more populations due to outcrossing would result in a larger 
proportion of heterozygosity in the genome and is termed mosaicism. While it is difficult to 
distinguish heterozygosity created by outcrossing from that created by mutation accumulation, 
the finding that 63% of wild isolates are heterozygotes despite a prevalence of asexual 
reproduction suggests that the heterozygous state is advantageous [9]. 
Advantages of heterozygosity. High levels of heterozygosity, especially in clinical 
isolates, points toward a heterosis-like advantage that allows for adaptation and survival in 
particular environments. Heterozygous genotypes allow meiotic progeny to explore larger 
genotypic and consequently phenotypic spaces, which can lead to survival under a variety of 
stress conditions [39, 42]. This advantage is demonstrated by the variation seen in the 
phenotypes of meiotic progeny of the clinical isolate YJM311 [37, 42, 43], and in the variation in 
mutation rate of meiotic progeny of the clinical isolates YJS5845 and YJS5885 ([10]; Table 1.3). 
How is heterozygosity maintained? Baker’s yeast is primarily homothallic and capable of 
self-mating, and so it seems surprising that high levels of heterozygosity are maintained in 
natural isolates. The frequency of heterothallism (inability to switch mating-type to form 
diploids) was reported to be higher in clinical isolates than non-clinical isolates [39]. For 
example, based on genotyping of the HO locus, Muller and McCusker [39] observed that four of 
eight clinical heterozygous isolates were heterothallic, indicating they would thus support 
maintenance of heterozygosity. The heterozygote advantage may select for the heterothallic 
phenotype in these isolates. Raghavan et al. [10] showed that one of two clinical isolates studied 
was functionally heterothallic, with its meiotic spore progeny remaining haploid. This isolate did 
not have any defects in the open reading frame of the HO gene, so there are likely to be 
mutations in other loci in this isolate that confer a heterothallic phenotype. Interestingly, 
Magwene et al. [15] reported in a set of 28 natural isolates that there was a seven-fold higher 
sporulation efficiency in homozygous compared to heterozygous isolates. Thus, lower 
sporulation efficiency may alsoplay a role in maintaining heterozygosity. It would be interesting 
to see if this correlation holds for the 1011 isolates studied in Peter et. al. [9]. 
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Table 1.2: Adaptive mechanisms observed in S. cerevisiae clinical isolate studies. 
 
Adaptive 
mechanism 
Description 
Multi-site 
heterozygosity 
794 natural isolates [9] 
• 46% of 107 clinical origin isolates were heterozygous 
• 66% of 687 non-clinical origin isolates were heterozygous 
Higher levels of heterozygosity in clinical isolates [15] 
• 37%-59% of total SNPs were heterozygous in clinical isolates  
• 0.9-15% of total SNPs were heterozygous in other isolates 
Mosaicism 
1011 natural isolates [9] 
• 47% clinical isolates belong to mosaic clades 
• 11% non-clinical isolates belong to mosaic clades 
144 natural isolates [8] 
• Approximately 19% of the 132 clinical isolates belong to mosaic 
clades 
• None of the 12 non-clinical isolates are mosaics 
100 natural isolate segregants [11] 
• 63% of 43 clinical strains belong to mosaic clades 
• 33% of 57 non-clinical strains belong to mosaic clades 
High mutation 
rate 
Clinical isolates YJS5885 and YJS5845 with a genetic incompatibility in 
mismatch repair genes MLH1 and PMS1 generate spore clones with a range 
of mutation rates [10]. 
Aneuploidy 
1011 natural isolates [9] 
• 19% of 904 non-clinical isolates are aneuploid, 7.2% of which have 
aneuploidies in more than one chromosome (two to nine). 
• 17% of 107 clinical isolates are aneuploid, 50% of which have 
aneuploidies in more than one chromosome (two to seven). 
144 natural isolates [8]. 36% contained aneuploidies, 132 of which are 
clinical isolates. Eight clinical isolates contained multiple aneuploidies. 
93 natural isolate segregants [11] 
• 5% of 47 clinical strains were aneuploid. 
• 10% of 50 non-clinical strains were aneuploid. Two contained 
multiple aneuploidies (one with two, the other with three). 
47 natural isolates [44] 
• 23.6% of 37 non-clinical natural isolates are aneuploid. Two of them 
had aneuploidies in multiple chromosomes. One had aneuploidy in 
two chromosomes and the other in four chromosomes. 
• 30% of 10 clinical isolates are aneuploid. One had aneuploidy in two 
chromosomes. 
Polyploidy 
794 natural isolates [9] 
16% of 505 non-clinical isolates are polyploid 
8% of 107 clinical isolates are polyploid 
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32% of 144 natural isolates are polyploid, 132 of which are clinical isolates 
[8]. 
30% of both clinical and non-clinical isolates are polyploid in a total of 137 
isolates [39]. 
 
  
  14 
 
Table 1.3: Heterozygosity in an isolate results in phenotypic range in its progeny: a few 
examples. 
 
Isolate Phenotype of spore clones 
YJM311 1. Varied resistance to the antifungal drug fluconazole [42]. Determined by 
measuring MIC50 (minimum concentration of fluconazole that inhibits 
50% growth) for 288 homozygous diploid spore clones. 
 2. Colony biofilm complexity [42, 43]. Colony morphologies of 288 spore 
clones were categorized visually ranging from simple, non-biofilm 
phenotype to highly complex biofilm colony morphology. 
 3. Varied invasive growth on agar [42]. Assessed by growing yeast on agar 
containing low ammonium, washing the surface growing cells and 
quantifying the levels of invasive growth. 
 4. Varied growth at 42ºC [37, 42]. Determined by measuring growth on 
agar plates at 42ºC for the 288 spores. 
YJS5885 1. 120-fold variation in mutation rate in 12 spore clones [10]. Determined 
by a frameshift reversion assay involving a plasmid containing a 
frameshift mutation in the gene encoding resistance for Geneticin. 
2. Variation in colony sizes in 12 spore clones as determined by growing on 
agar plates at 30ºC for 2 days [10]. 
YJS5845 1. 340-fold variation in mutation rate in 11 spore clones [10]. 
2. Variation in colony sizes in 11 spore clones [10]. 
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2. Mosaicism 
Different isolates can often colonize and cause infection in individual immune-deficient patients. 
Such multiple isolate infections can provide an opportunity for isolates to outcross and generate 
mosaics [8, 11, 16, 45]. Isolates are classified as mosaics if their genomes contain sequences 
derived from more than one genetically diverse ancestor. Importantly, they may also contain 
high levels of genomic heterozygosity if the outcrossing events occurred relatively recently. 
Human influence is likely to play a major role in bringing different isolates together and 
generating stress conditions that promote outcrossing between such isolates. Thus, it is not a 
surprise that a majority of the isolates that are mosaics are isolated from human-related (e.g., 
clinical and wine isolates) rather than natural environments ([8, 9, 11], Table 1.2). Additionally, 
a high proportion of clinical isolates belong to mosaic clades; 47% of clinical isolates compared 
to 11% of non-clinical isolates, belong to mosaic clades, though it is important to note that a 
significant number of clinical isolates are part of the wine clade ([8, 9, 11], Table 1.2). 
 Outcrossing between different isolates with varying degrees of adaptive potential will 
likely lead to the generation of mosaic isolates with higher adaptive potentials because they 
would contain new and unexplored combinations of genes and alleles that facilitate adaptation to 
new environments. Mosaicism may also aid in adaptation by providing a phenotypic range in the 
progeny as mentioned above for heterozygosity. 
 
3. High mutation rates  
High mutation rates can accelerate adaptation to stress conditions because they provide an 
elevated mutation supply that can more rapidly yield beneficial mutations. Bacteria that display 
high mutation rates are frequently found in nature [46-53]; however, modeling analyses and 
molecular studies indicate that bacteria prevent the long-term fitness cost of accumulating 
deleterious mutations through the horizontal transfer of genes that restore a low mutation rate 
[48, 52, 54]. Horizontal gene transfer events are rare in fungi [55, 56], and baker’s yeast active 
mutators have yet to be isolated in natural environments. Recently, active mutators were 
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identified in clinical isolates of the human fungal pathogen Cryptococcus that contain mutations 
in the mismatch repair gene MSH2 [57, 58], demonstrating that a high mutation rate can provide 
beneficial mutations for adaptation in fungi despite the associated fitness costs. 
Outcrossing between isolates with high sequence divergence can result in the creation of 
novel mutator combinations of non-mutator variants in different genes. For example, mating 
between two laboratory baker’s yeast strains can yield progeny that display mutator phenotypes 
due to the presence of an incompatible combination of the MLH1 and PMS1 mismatch repair 
genes which act in a highly conserved pathway to remove DNA replication errors [10, 59]. The 
proteins Mlh1 and Pms1 function as a heterodimer, and a specific incompatible combination of 
single amino-acid polymorphisms in Mlh1 and Pms1 results in elevated mutation rates [60], 
which can provide an adaptive advantage to stress [61]. In the heterozygous clinical isolates 
YJS5885 and YJS5845, which are not mutators, MLH1-PMS1 incompatibility acts as a major 
contributor to high mutation rates seen in spore clones derived from either isolate [10]. 
Interestingly, these spore clones displayed a wide range of mutation rates, indicating the 
presence of extragenic suppressors and enhancers of mutation rate ([10], Figure 1.2A). 
MLH1-PMS1 incompatibility allele combinations are rare in nature, most likely due to 
the detrimental effects of defects in mismatch repair on fitness [59]. Analysis of the patterns of 
sequence polymorphisms in DNA encompassing the PMS1 locus provided evidence that 
recombination to generate incompatible genotypes had occurred in the past, suggesting that 
natural isolates of baker’s yeast do mate and occasionally produce the incompatible genotype 
[60]. Only one isolate among 1011 natural isolates was found to be homozygous for the 
incompatibility genotype, but a spore clone of this isolate had acquired suppressor mutations and 
was not a mutator [9, 45, 59]. However, a diploid strain containing an MLH1-PMS1 
incompatibility in the heterozygous state may have an advantage because the incompatibility is 
recessive and the effect of incompatibility is only observed in spore progeny [10]. The presence 
of the MLH1-PMS1 incompatibility could thus provide a transient advantage for adaptation, with 
  17 
mutator spore clones adapting to a stress condition and escaping fitness costs by acquiring 
suppressors, mating to nearby spore clones, or outcrossing to become non-mutators [10]. 
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Figure 1.2. Mutation rate variation and aneuploidy in a clinical isolate. A. Mutation rates 
were determined using a plasmid-based frameshift reversion assay of an MLH1-PMS1 
compatible laboratory strain (S288c) and an isogenic derivative containing an incompatible 
MLH1-PMS1 combination. The mutation rates of the heterozygous diploid clinical isolates 
YJS5845 and YJS5885 were also determined, as well as the rates for six compatible and five 
incompatible spore clones of YJS5845 and eight compatible and four incompatible spore clones 
of YJS5885. Larger variations in mutation rate were observed between incompatible and 
compatible spore clones of YJS5845 (340-fold) and YJS5885 (120-fold) compared to the S288c 
laboratory strain (11-fold). B. Whole genome sequencing of clinical isolate YJS5845 and 16 
spore clones identified aneuploidy in the isolate and two of the spore clones. This isolate had a 
trisomy of chromosome XIV, one spore clone had a trisomy of chromosome XI, and the other 
spore clone had a monosomy of chromosome I. Figure adapted from Raghavan et al. [10]. 
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4. Aneuploidy 
A change in the chromosome number from the euploid set is referred to as aneuploidy; in most 
cases such events are deleterious to the cell. Effects of aneuploidy could be mediated by a direct 
change in the expression of genes on the aneuploid chromosome due to copy number variation, 
or be an indirect effect due to a change in expression of a gene that regulates targets located 
throughout the genome [62]. Additionally, there could be a general effect of aneuploidy that is 
not specific to a particular chromosome. As shown by Torres et al. [63], an extra copy of almost 
any yeast chromosome caused a reduction in cellular proliferation, which was attributed to 
altered levels of gene products encoded by genes that reside on the extra chromosome. In 
organisms such as Drosophila, C. elegans, mice, plants and humans, most aneuploidies are lethal 
[64]. Aneuploidies are observed in almost all cancerous cells, and it is debated whether they are a 
consequence of chromosome instability and segregation defects, or they are direct drivers of 
cellular transformation [64]. 
Despite conferring negative fitness effects, aneuploidy has been commonly observed in 
natural baker’s yeast and may provide an important route to natural genetic variation. 
Aneuploidy has been suggested to help in adaptation in environments with human association 
such as in brewing, baking and wine strains of yeast [65]. In a study of 1011 natural isolates, 
Peter et al. [9] observed aneuploidy in 19% of isolates, and Strope et al. [11] reported 7.5% 
aneuploidy in 100 S. cerevisiae isolates obtained from various different geographical sources 
(Table 1.2, with other examples provided). Furthermore, aneuploid isolates may be more likely 
to generate aneuploid progeny, as seen in the clinical isolate, YJS5845 ([10], Figure 1.2B). This 
isolate was a mix of aneuploid and euploid cells, probably generated due to mitotic chromosome 
segregation defects. When sporulated in the laboratory, two of sixteen spore clones displayed 
aneuploidies in different chromosomes [10]. 
In certain circumstances, the beneficial effects of aneuploidy could offset negative effects 
on cell survival [66, 67]. Aneuploidy appears to be one of the first lines of defense to stress that 
increases chances for survival under strong and abrupt selective pressures [67]. In baker’s yeast, 
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sudden stress conditions induced in the laboratory selected for aneuploidy, with loss of 
aneuploidy occurring when the stressor was removed [67]. When the stress condition was 
maintained, aneuploidy was lost in about 2,000 generations, with a more stable solution obtained 
through mutations that modified the expression of stress resistance genes, as seen by Yona et al. 
for heat stress [44, 67]. Thus, aneuploidy may be a valuable mechanism for adaptation in clinical 
isolates, which live in an environment with variable and sudden stressors. 
How is aneuploidy tolerated? In many situations, an extra chromosomal copy provides 
tolerance to a particular stress condition [66]. For example, extra chromosomal copies confer 
resistance to heat (Chr. III), high pH (Chr. V), and the ultra violet light mimetic mutagen 4-
Nitroquinoline 1-oxide (Chr. XIII) [66, 67]. Aneuploid isolates appear to better tolerate 
chromosome gains or losses due to dosage compensation mechanisms [44, 68]. In support of 
this, Hose et al. [44] analyzed twelve isolates containing an extra chromosome. They found that 
for 40% of genes located on such a chromosome, gene expression levels were lower than 
expected based on their dosage [44]. Furthermore, in contrast to artificially created aneuploids in 
the laboratory, natural aneuploids had growth rates similar to closely related euploids [44]. 
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5. Polyploidy 
Baker’s yeast is most commonly diploid in nature, but polyploidy has been associated with 
human interference in natural isolates of yeast [8, 9]. Peter et al. [9] found that 87% of 794 
natural isolates were diploid and 11.4% were polyploid. These polyploid isolates were enriched 
in human associated environments including beer, mixed-origin and African palm wine clades, 
although there was no significant enrichment in clinical isolates ([9], Table 1.2). Muller and 
McCusker [39] analyzed a diverse natural population and estimated that 70–80% of their isolates 
were diploid, with the remaining 20–30% of isolates being triploid or tetraploid, and Cubillos et 
al. [69] found that 95% of a group of more than 200 wine strains were diploid. Polyploidy has 
also been observed in clinical isolates [8, 39]. Zhu et al. [8] showed in a study of 144 isolates, 
the majority of which were clinical (132), that 34% were polyploid. 
In baker’s yeast, polyploid genomes are less stable than haploid and diploid genomes, 
and have been hypothesized to act as drivers of adaptation [39]. Polyploid baker’s yeast display 
genetic instability phenotypes that are thought to arise as a result of their tendency to mis-
segregate chromosomes [38, 70-72]. Consistent with this idea, polyploid baker’s yeast genomes 
are associated with a more than a two-fold increase in aneuploidy [8] and also display higher 
mutation rates [38, 73]. Such ploidy-specific effects are thought to facilitate adaptation by 
creating larger genotypic and phenotypic spaces, and the higher numbers of chromosomes in 
polyploids are thought to buffer the effects of deleterious mutations [38, 73]. Laboratory 
evolution experiments support these ideas, but such support depends on the stress condition used 
[38, 74]. For example, Selmecki et al. [38] compared adaptation of tetraploid, diploid, and 
haploid S. cerevisiae to a low carbon environment and found that tetraploids adapted 
significantly faster. This more rapid adaptation was due to a higher rate of beneficial mutations 
as well as a higher fitness conferred by the mutations [38]. In contrast, Gerstein et al. showed in 
C. albicans that both higher and lower ploidy states can be advantageous under different stress 
conditions [74]. Since polyploidy can be beneficial in adaptation by multiple mechanisms, it may 
be used by clinical isolates to adapt to the unpredictable environment of the human host.  
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Conclusions and Future Directions 
Adaptation to novel stress environments often requires organisms to incur genetic changes. Such 
changes can be accelerated in organisms by high mutation rates, acquiring specific stress 
resistance genes through horizontal gene transfer, or genomic instabilities that lead to 
chromosome gains and losses. Clinical yeast isolates have been subjected to novel and repeated 
stresses aimed at suppressing their growth and survival. Thus, they must be able to rapidly and 
repeatedly adapt to stress conditions to survive such conditions. As summarized in this review, 
multi-site heterozygosity, mosaicism, transient high mutation rates, aneuploidy, and polyploidy 
appear to be major sources of genetic raw material for adaptation in baker’s yeast.  
Analyzing more extensive collections of S. cerevisiae isolates from hospitals will be 
critical to determine more precisely the prevalence of phenotypes and genetic mechanisms that 
lead to these phenotypes. A plasmid-based mutator assay based on reversion to antibiotic 
resistance can allow for a more rapid analysis of mutator phenotypes in natural/clinical isolates 
and their spore clones [10, 59]. Such an approach may also be used to identify loci in natural 
isolates that impact mutation rate [75-77]. 
Molecular evolution studies performed with baker’s yeast grown under different stress 
conditions have identified beneficial mutations that drive adaptation and propagate the 
population [75, 76]. These studies were performed by barcoding individual cells and tracking 
their lineages through whole genome sequencing to identify adaptive mutations. Such methods 
will be helpful to identify adaptive mutations in clinical yeast isolates grown in a mouse model. 
It is clear that excessive use of antifungals plays an important role in the generation of 
fungal infections. Their use can result in the development of multi-drug resistant fungi [25, 26] 
and also affect the protective commensal fungal population that aids in immunity [26]. The use 
of live cultures of S. cerevisiae and S. boulardii in probiotics has also resulted in infections in 
immunocompromised patients [5, 21, 77]. The indiscriminate use of these antifungals should be 
restricted; we need to re-think the use of S. cerevisiae in probiotic preparations. Additionally, 
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learning more about adaptation mechanisms and genetic signatures of clinical isolates would 
help in generation of anti-fungal drugs to fight these infections. 
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Outstanding questions  
 
How prevalent are phenotypes such as high temperature growth, resistance to antifungal drugs, 
colony phenotype switching, and pseudohyphal growth in clinical yeast isolates? Have all loci 
been identified that are responsible for these phenotypes? 
 
How frequently are heterozygosity, mosaicism, high mutation rates, aneuploidy and polyploidy 
seen in clinical isolates that facilitate adaptation?  
 
Can loci be mapped that enhance or suppress mutation rates in natural isolates and their spore 
clones? 
 
Adaptive evolution experiments have yet to be performed for clinical yeast isolates grown in an 
immune-compromised mouse model. What are the evolutionary landscapes and mutational 
signatures that accompany adaptation of clinical yeast isolates in a mammalian host 
environment?  
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Glossary 
 
Isolate An isolate is found in nature, whereas a strain has been 
manipulated in the laboratory. 
Outcrossing Mating between genetically different strains/isolates. 
Mosaic Mixed genotype derived from two or more genetically different 
populations. An isolate is classified as mosaic when it has multiple 
sources of ancestry and when it has less than 60% ancestry from 
any one population [11]. Mosaic isolates are polymorphic for a 
majority of segregating sites and are derived from outbreeding [9, 
14]. They frequently manifest as isolated branches on a 
phylogenetic tree [9].  
Homothallic Baker’s yeast cells that have the ability to undergo mating type 
switching. This allows mating (auto-diploidization) between 
mother and daughter cells.  
Heterothallic Baker’s yeast cells that cannot undergo mating type switching and 
can be maintained as stable haploids. 
Autodiploidization Mating between mother and daughter cells after mating type 
switching. 
Heterosis Higher fitness of the hybrid resulting from mating between 
different strains/isolates. Also referred to as hybrid vigor. 
Multi-site heterozygosity Allelic variation seen in the same individual at multiple genetic 
loci. Peter et al. [9] classified heterozygous isolates having more 
than 5% heterozygous sites out of a total number of SNPs (single 
nucleotide polymorphisms) compared to the reference genome 
S288c. In 1011 isolates, heterozygosity ranged from 0.63-6.56 
SNP sites per kilobase in heterozygous isolates [9]. There were 
2,000-78,000 total heterozygous SNPs in the 1011 isolates [9]. 
Aneuploidy Loss or gain of one or few chromosomes that causes a change in 
the chromosome number from a multiple of the haploid set. 
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Polyploidy Having more than two complete sets of chromosomes, e.g.: triploid 
has three copies of each chromosome.  
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Abstract  
Laboratory baker’s yeast strains bearing an incompatible combination of MLH1 and 
PMS1 mismatch repair alleles are mutators that can adapt more rapidly to stress but do so at the 
cost of long-term fitness. We identified 18 baker’s yeast isolates from 1011 surveyed that contain 
the incompatible MLH1-PMS1 genotype in a heterozygous state. Surprisingly, the incompatible 
combination from two human clinical heterozygous diploid isolates, YJS5845 and YJS5885, 
contain the exact MLH1 (S288c derived) and PMS1 (SK1 derived) open reading frames 
originally shown to confer incompatibility. While these isolates were non-mutators, their meiotic 
spore clone progeny displayed mutation rates in a DNA slippage assay that varied over a 340- 
fold range. This range was 30-fold higher than observed between compatible and incompatible 
combinations of laboratory strains. Genotyping analysis indicated that MLH1-PMS1 
incompatibility was the major driver of mutation rate in the isolates. The variation in the 
mutation rate of incompatible spore clones could be due to background suppressors and 
enhancers as well as aneuploidy seen in the spore clones. Our data are consistent with the 
observed variance in mutation rate contributing to adaptation to stress conditions (e.g. in a 
human host) through the acquisition of beneficial mutations, with high mutation rates leading to 
long-term fitness costs that are buffered by mating, or eliminated through natural selection.  
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Introduction  
Loss of DNA mismatch repair (MMR) functions is often seen in bacteria grown in 
stressful environments. MMR defective bacteria display an increased mutation supply and adapt 
to stress by acquiring beneficial mutations; however, their high mutation rate ultimately results in 
the accumulation of deleterious mutations that reduce fitness [1-8]. Bacteria defective in MMR 
can overcome fitness costs associated with high mutation rate by regaining MMR functions 
through horizontal gene transfer [5]. In baker’s yeast loss of MMR functions in the laboratory 
provides an adaptive advantage to stress [9-11]. However, there is no evidence that baker’s yeast 
defective in MMR can undergo horizontal transfer in the wild [12-14]. We and others 
hypothesized that MMR defective baker’s yeast isolates in the wild could potentially mate to 
MMR proficient isolates to become non-mutators and thus eliminate long term fitness costs 
(reviewed in Bui et al., [15]).  
S. cerevisiae are usually non-pathogenic and are infectious only in immunocompromised 
individuals, causing opportunistic infections [16, 17]. Phylogenetic analyses of sixteen human 
clinical isolates indicated that these isolates were not derived from a common ancestor or single 
strain but may be a consequence of multiple independent origins arising from chance events 
involving opportunistic colonization of human tissues by different strains [18-21]. Yeast strains 
that infect humans must survive unfavorable growth conditions such as elevated temperature and 
exposure to antifungal agents. Interestingly, recent studies have suggested that ploidy changes 
and chromosome aneuploidy can promote phenotypic diversity; in some cases, such events are 
thought to increase the rate of acquiring adaptive mutations in the face of stress and have been 
seen at higher frequencies in clinical isolates [20, 22-31]. At present it is unclear if baker’s yeast 
  38 
strains associated with humans can be MMR defective; however, two recent reports identified 
Cryptococcus fungal human pathogens that are defective in MMR and are mutators [32, 33]. 
We showed previously that the MLH1 and PMS1 mismatch repair genes from S288c and 
SK1 yeast strains can display negative epistasis; strains bearing the S288c MLH1-SK1 PMS1 
genotype are mutators [34]. Single amino acid changes in each protein, MLH1 D761 from 
S288c, PMS1 K818/822 from SK1, were sufficient to cause this incompatibility (Figure 2.1; 
[34]). The MLH1-PMS1 combinations are compatible in the S288c and SK1 group strains as well 
as in the inferred ancestral strain from which they diverged (Figure 2.1, [11, 34]). The 
incompatible combination of S288c MLH1-SK1 PMS1 in laboratory strains (abbreviated as 
cMLH1-kPMS1) confers an ~100-fold increase in the mutation rate in an assay in which null 
mutants display a 10,000-fold higher rate [11, 34]. Incompatible strains have an adaptive 
advantage in high salt stress [11]. However, they also display a long-term fitness cost due to the 
accumulation of deleterious mutations. This was demonstrated by a fitness decline of 
incompatible cells in competition experiments between compatible and incompatible cells in rich 
media [15]. To our knowledge the cMLH1-kPMS1 genotype is the only incompatibility involving 
mismatch repair genes that has been characterized. However, recessive mutations in mismatch 
repair genes MSH2 and MSH6 found in colon cancer patients were postulated to be due to a 
compound effect of mutations in the two genes, which could reflect negative epistasis [35].   
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Figure 2.1: Incompatibility involving the MLH1 and PMS1 MMR genes. In the model 
presented, ancestral isolates bearing MLH1 Gly 761 and PMS1 Arg 818/822 alleles acquire 
neutral or beneficial mutations that lead to the derived S288c (purple, Asp 761, Arg 818/822) 
and SK1 (green, Gly 761, Lys 818/822) group isolates. Matings between derived isolates yield 
an allele combination (MLH1 Asp 761, PMS1 Lys 818/822) that displays negative epistasis, 
revealed as a mutator phenotype. Previous work suggested that recombination occurred between 
the two derived classes, leading to a hybrid mutator genotype that can also remate to reconstruct 
derived or ancestral genotypes [34]. In this figure, sequences of MLH1 and PMS1 genes from 
1,011 S. cerevisiae from worldwide genome collections are grouped according to their amino 
acid residues 761 (G or D) in MLH1 and 818 (R or K) in PMS1 [15]. One isolate maps to the 
predicted hybrid mutator category. Adapted from Bui et al. [15].   
Homozygous genotypes: 904 isolates
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In a search for yeast bearing the incompatible cMLH1-kPMS1 combination, we screened 
a collection of 1011 naturally occurring worldwide isolates of Saccharomyces cerevisiae [15, 
36]. Only YJM523, a human clinical isolate of S. cerevisiae, is homozygous for cMLH1-kPMS1 
incompatibility [15, 19, 21]. A spore clone of YJM523, YJM555, was a non-mutator that had 
accumulated multiple suppressors of the incompatibility phenotype [15, 21]. To our knowledge 
baker’s yeast isolates that are mutators have not been identified in the wild [15, 21]. However, 
yeast heterozygous for the cMLH1-kPMS1 incompatibility, a recessive trait [34], might have an 
advantage because they can be non-mutators in a heterozygous diploid background. Under stress 
conditions the diploids can sporulate and give rise to mutator spore clones. These mutators 
would be able to provide a transient adaptive advantage to stress and can potentially mate back to 
compatible strains and become non-mutators to prevent long-term fitness costs.  
In eukaryotes, a complete loss of MMR functions would likely have dramatic effects on 
organism fitness. In changing environments, as would likely be the case for yeast growing in a 
human host, adaptation to stress would involve a compromise between efficient growth and long-
term survival. One way to deal with such variable stress is for progeny of an organism to display 
variations in mutation supply that can yield adaptation phenotypes and thus prevent the 
population from undergoing extinction under stress (see [37]). We examined two human clinical 
diploid isolates, YJS5845 and YJS5885, that are each heterozygous for cMLH1-kPMS1 
incompatibility polymorphisms. In both isolates, one of the two copies of MLH1 is identical in 
amino acid sequence to S288c MLH1, and one of two copies of PMS1 is identical to SK1 PMS1. 
The isolates were non-mutators but derived spore clones displayed a 340-fold range of mutation 
rates in a DNA slippage assay, with cMLH1-kPMS1 incompatibility being the major contributor 
to increased mutation. In contrast, the difference in mutation rates between laboratory-
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compatible and incompatible strains was only eleven-fold, indicating that the human isolate 
backgrounds contained suppressors and enhancers of mutation rate. Curiously, high levels of 
aneuploidy were observed in the spore clones from YJS5845, suggesting additional mechanisms 
that may contribute to modifying mutation rate and/or adaptation. These findings suggest that 
there is a variation in mutation supply that is balanced with associated fitness costs. Such 
variation could provide a greater chance for yeast to survive stress conditions present in a human 
host.  
Materials and Methods  
S. cerevisiae strains and media  
The natural isolates YJS5845, YJS5885, YJS4806, YJS4810, YJS5882, YJS5678, 
YJS5512, and YJS4970 (Table 2.3) were obtained from the 1011 Yeast Genomes Project [36]. 
YJM521, YJM523 and YJM555 were obtained from the FGSC collection ([19]; 
http://www.fgsc.net/). Isolates were sporulated on plates by streaking cells from frozen stocks 
onto YPD (2% peptone, 1% yeast extract, 2% dextrose) media. Cells were grown for one day at 
30°C, after which they were patched onto sporulation medium (1% (g/L) potassium acetate, 2% 
(g/L) agar) and incubated at 30°C for 3 days. Tetrads were dissected and germinated on minimal 
complete media [38]. Isolates were sporulated in liquid by growing overnights in YPD. 50 μl of 
each overnight was then inoculated into 5 ml YPA (2% peptone, 1% yeast extract, 2% potassium 
acetate) media and grown with shaking at 30°C for 16 hours, after which each culture was 
washed with 3 ml of sterile water and then transferred to 1% potassium acetate and incubated at 
30°C with shaking for 3 days. In order to test for growth of spore clones in lactate media, spore 
clones were patched on YPL plates (2% peptone, 1% yeast extract, 2% lactate, 2% agar) and 
grown for 4 days at 30°C (Table 2.8).  
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The S288c derived strains EAY1365 (MATa, ura3-52, leu2Δ1, trp1Δ63, his3Δ200, 
lys2::insE-A14, mlh1Δ::KanMX4, pms1Δ::KanMX4), EAY1369 (MATalpha, ura3-52, leu2Δ1, 
trp1Δ63, his3Δ200, lys2::insE-A14, cPMS1::HIS3, cMLH1), EAY1370 (MATalpha, ura3-52, 
leu2Δ1, trp1Δ63, his3Δ200, lys2::insE-A14, kPMS1::HIS3, cMLH1), EAY1372 (MATa, ura3-52, 
leu2Δ1, trp1Δ63, lys2::insE-A14, msh2D::hisG), FY90 (MATa, ade8; Winston et al. 1995) and 
EAY4087 (MATa, ade8, mlh1D::KanMX), and the natural isolates YJS5845 and YJS5885 and 
their spore clone derivatives were analyzed for mutator phenotypes (see below for details). 
Transformation of plasmids into strains, isolates and spore clones was performed as described 
[39]. In this manuscript, genes derived from the S288c background are designated with a “c” 
(e.g. cMLH1) and those derived from SK1 with a “k” (e.g. kMLH1).  
Plasmids  
pEAA213 (cMLH1, ARSH4 CEN6, LEU2) and pEAA214 (kMLH1, ARSH4 CEN6, 
LEU2) were described previously [34, 40]. The cMLH1 gene from YJM521 was cloned into 
pEAA213 as described previously [15]. All of the constructs expressed MLH1 via the S288c 
MLH1 promoter. pEAA238 (cPMS1, ARSH4, CEN6, HIS3) and pEAA239 (kPMS1, ARSH4, 
CEN6, HIS3) were described previously [34, 40]. The kPMS1 gene from YJM521 was cloned 
into pEAA238 as described previously [15]. All of the constructs expressed PMS1 via the S288c 
PMS1 promoter.  
pEAA613 (ARS-CEN, NATMX) contains the URA3 promoter-KanMX::insE-A14 reversion 
reporter [15]. This reporter is expressed via the URA3 promoter (-402 to the ATG start site). A 
55 bp sequence containing a +1 frameshift in the 14 bp homopolymeric A run (insE-A14; [41]) 
was inserted immediately after the URA3 ATG, followed by codons 18 to 269 of the KANMX 
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open reading frame derived from pFA6-KANMX. pEAA611 (ARS-CEN, NATMX) contains the 
URA3 promoter-KanMX::insE-A10 in frame reporter [15]. 
 
Genotyping analysis  
The 2.3 kb MLH1 and 2.6 kb PMS1 open reading frames from YJM521, YJS5845, 
YJS5885, YJS4806, YJS4810, YJS5882, YJS5678, YJS5512, YJS4970 and derived spore clones 
were determined by sequencing PCR amplified DNA from chromosomal DNA (Table 2.1; Table 
2.2; [42]) using Expand High Fidelity Polymerase (Roche Life Sciences). Primers AO324 
(5’ATAGTGTAGGAGGCGCTG) and AO821 
(5’AACTTTGCGGCCGCGGATCCAGCCAAAACGTTTTAAAGTTA) were used to amplify 
the MLH1 open reading frame and primers AO481 
(5’CCACGTTCATATTCTTAATGGCTAAGC) and AO548 
(5’CGATTCTAATACAGATTTTAATGACC) were used to amplify the PMS1 open reading 
frame. PCR products were sequenced by the Sanger method in the Cornell Biotechnology 
Resource Center.  
The diploid isolates YJM521, YJS5845, and YJS5885 were shown previously to be 
heterozygous for genetic information at both the MLH1 and PMS1 incompatibility sites (Gly/Asp 
at amino acid 761 in MLH1, Arg/Lys at amino acid 818/822 in PMS1; [15, 21]). For each diploid 
isolate, the sequences of the two MLH1 and PMS1 alleles were determined by sequencing the 
MLH1 and PMS1 genes from two ancestral (MLH1 Gly 761, PMS1 Arg 818/822) and two 
incompatible (MLH1 Asp 761, PMS1 Lys 818/822) haploid spore clones. In all cases the DNA 
sequences of the two different spore clone isolates of the same MLH1-PMS1 genotype were 
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identical, thus allowing us to assign the MLH1 and PMS1 sequences present in each parental 
chromosome (Table 2.2).  
To determine the compatibility genotype (Gly/Asp at amino acid 761 in MLH1, Arg/Lys 
at amino acid 818/822 in PMS1; Figure 2.1; Figure 2.2) of YJM521, YJS5845, and YJS5885 
spore clones, MLH1 and PMS1 open reading frame PCR products were sequenced with primers 
AO328 (5’ GACGAGTTAAATGACGATGCTTCC) and AO485 (5’ 
AAAGTATCTGACGTTAACAGTTTC), respectively. To test for the presence of the proline 
271 suppressor polymorphism in MLH1 incompatible spore clones [43] in YJS5845 and 
YJS5885, MLH1 PCR products were also sequenced using primer AO325 (5’ 
CATGTGGCAACAGTCACAGTAACG). None of the spore clones (10 from YJS5845, 11 from 
YJS5885) contained this polymorphism, displaying instead the leucine residue.  
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Table 2.1: Genotyping of spore clones obtained by dissection of isolate tetrads 
 
   Number of spore clones genotyped for 
MLH1-PMS1 as: 
Lab name MLH1 genotype 
PMS1 
genotype Ancestral SK1 S288c Incompatible 
       
YJS5845 SK1/S288c SK1/S288c 5 17 1 10 
YJS5885 SK1/S288c SK1/S288c 5 6 11 11 
YJM521 SK1/S288c SK1/S288c 5 7 7 5 
YJS4806 SK1/S288c (3:1) SK1 not relevant    
YJS4810 SK1/S288c (3:1) SK1 not relevant    
YJS5882 SK1/S288c (3:1) 
SK1-S288c 
(2:2) not relevant 
   
YJS5678 SK1/S288c (3:1) 
SK1/S288c 
(2:2) not relevant 
   
YJS5512 SK1/S288c (3:1) 
SK1/S288c 
(2:2) not relevant 
   
YJS4970 SK1/S288c (2:2) 
SK1/S288c 
(2:2) not relevant 
   
 
MLH1 and PMS1 genes were PCR amplified from isolates and derived spore clones and 
sequenced as described in the Materials and Methods. For YJS5845, three spore clones were 
genotyped from random spores and 30 were genotyped from spores isolated after tetrad 
dissection. For YJS5885 and YJM523, all spore clones were genotyped from tetrad dissection. 
None of the incompatible YJS5845 and YJS5885 spore clones contained the Pro 271 suppressor 
polymorphism in MLH1[43]. For YJM521, 24 spore clones were genotyped from six four-spore 
viable tetrads. For YJS4806, 24 spore clones were genotyped from random spores with 22 
showing the parental genotype for MLH1, and two showing a different segregation pattern 
(2G:2A, 4G:0A). For YJS4810, 24 spore clones were genotyped from random spores, with all 
showing the parental genotype for MLH1. 
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Table 2.2: Genotyping of MLH1 and PMS1 loci in YJM and YJS isolates and derived spore 
clones 
 
base pair  aa S288c SK1 YJS5845c  YJS5845k  YJS5885c  YJS5885k  YJM523  YJM521c  YJM521k  
           
MLH1           
486 162 C, ALA T, ALA C C C C C C C 
552 184 C, SER C, SER C C C C C T, SER C 
720 240 C, SER A, ARG C C C C C C C 
812  271 T, LEU C, PRO T C T C T C C 
834 278 C, SER T, SER C T C T C C T 
997 333 G, GLU A, LYS G G G G G G G 
1044 348 T, ILE C, ILE T C T C T T C 
1237 413 T, LEU C, LEU T C T C T T C 
1393 465 G, ASP G, ASP G G G G G A, ASN G 
1875 625 T, SER C, SER T C T C T T C 
2032 678 G, ASP A, ASN G A G A G G A 
2108 703 C, PRO T, LEU C T C T C C T 
2282  761 A, ASP G, GLY A G A G A A G 
          
PMS1           
122 41 A, ASN G, SER G G G G A A A 
162 54 T, SER T, SER T T T C T T T 
177 59 T, ASP T, ASP T T T T C, ASP T C, ASP 
210 70 G, GLU G, GLU G G G G A, GLU G A, GLU 
213 71 C, PHE T, PHE T T T T T C T 
258 86 T, ASP C, ASP C C C C C C C 
333 111 G, VAL C, VAL C C C C C C C 
335 112 T, ILE C, THR C C C C T T T 
465 155 C, PRO T, PRO T T T T T C T 
552 184 T, ALA A, ALA T A T A T T T 
558 186 T, ILE C, ILE C C C C C T C 
708 236 A, LEU G, LEU G G G G G A G 
711 237 T, ASN C, ASN C C C C C T C 
810 270 G, SER C, SER G C G C G G G 
855 285 G, VAL A, VAL G A G A G G G 
858 286 T, ASN T, ASN T T T T C, ASN T C, ASN 
918 306 C, PHE C, PHE C C C C C T, PHE C 
925 309 G, VAL G, VAL G G G G G T, PHE G 
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939 313 T, ALA A, ALA A A A A A T A 
base pair  aa S288c SK1 YJS5845c  YJS5845k  YJS5885c  YJS5885k  YJM523  YJM521c  YJM521k  
1150 384 T, PHE G, VAL G G G G G T G 
1175 392 A, GLU A, GLU A A A A T, ASP A T, ASP 
1191 397 C, ASN C, ASN T, ILE C T, ILE C T, ILE C T, ILE 
1199 400 C, THR G, SER G G G G G C G 
1201 401 G, ALA G, ALA T, SER G T, SER G T, SER G T, SER 
1249 416 NO INS INS  INS  INS  INS  INS  INS  NO INS  INS  
1329 443 C, ILE C, ILE T, ILE C C C T, ILE C T, ILE 
1538 513 A, TYR T, PHE A T A T A A A 
1575 525 G, ALA C, ALA G C G C G G G 
1691 564 C, ALA C, ALA C C C C T, VAL C T, VAL 
1782 594 T, TYR C, TYR C C C C C T C 
1821 607 A, GLU G, GLU G G G G G A G 
2076 692 T, ASP T, ASP C, ASP T T T T T T 
2303 768 A, LYS A, LYS A A A A G, ARG A G, ARG 
2322 774 T, THR G, THR G G G G G T G 
2364 788 G, LEU A, LEU A A A A A G A 
2453  818 G, ARG A, LYS G A G A A G A 
 
The sequences for the MLH1 and PMS1 open reading frames for each of the two parental 
chromosomes are shown relative to the S288c and SK1 sequences for YJS5845, YJS5885, and 
YJM521. The parental chromosomes were genotyped as “c” (S288c) or “k” (SK1) based on the 
amino acid polymorphisms seen at the incompatibility loci (bp 2282 in MLH1, bp 2453 in PMS1) 
in the S288c and SK1 sequences (Materials and Methods). The MLH1-271P suppressor allele is 
highlighted at bp 812 in MLH1. INS = 12 bp insertion in PMS1; NO INS = lacking the insertion. 
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Efficiency of plating  
EAY1369 (cMLH1-cPMS1, compatible) and EAY1370 (cMLH1-kPMS1, incompatible) 
strains, and YJM521, YJM555, YJS5845, and YJS5885 isolates/spore clone derivatives were 
transformed with pEAA611 (URA3 promoter-KanMX::insE-A10 in frame reporter; [15]), and 
grown on YPD media containing clonNAT (100 μg/ml). Independent transformants were grown 
overnight on YPD-clonNAT (50 μg/ml). 10 μl of 100, 10-1, 10-2, 10-3, 10-3 and 10-4 dilutions 
were plated on YPD-clonNAT (50 μg/ml) and YPD-clonNAT (50 μg/ml) geneticin (200 μg/ml) 
plates. Growth on YPD-clonNAT and YPD-clonNAT, geneticin plates was compared and strains 
that grew to the same extent on both plates (within a few fold variation) were considered to have 
an efficiency of plating of ~1. Reversion assays were performed only on spore clones showing an 
efficiency of plating of ~1 (Figure 2.5).  
kanMX::insE-A14 reversion assay  
The S288c strain EAY1369 (cMLH1-cPMS1, compatible) and EAY1370 (cMLH1-
kPMS1, incompatible), and YJS5845 and YJS5885 isolates and spore clone derivatives were 
transformed with pEAA613 and grown on YPD media containing clonNAT (100 μg/ml). 
Independent transformants were subsequently grown overnight in YPD + clonNAT and then 
plated on to YPD + clonNAT (50 μg/ml) and YPD + clonNAT (50 μg/ml), geneticin (200 
μg/ml). These strains were analyzed for reversion to resistance to geneticin using methods 
described previously [11, 15, 41, 44]. Previously we measured resistance to geneticin (G418) for 
EAY1369 and YJM555 lacking the kanMX::insE-A14 reporter plasmid [15]. We estimated the 
mutation rates to be < 2 x 10-10, indicating that spontaneous reversion to G418r would not 
interfere with the detection of G418r using the pEAA613 kanMX::insE-A14 reporter plasmid. 
The 95% confidence intervals were determined as described by Dixon and Massey [45]. Mann-
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Whitney U tests were performed using Prism (GraphPad Prism 7.00 for Mac OS X, GraphPad 
Software, La Jolla California USA, www.graphpad.com) to determine the significance of the 
differences in median reversion rates [46, 47].  
 
Sequencing of homopolymeric A repeats in kanMX::insE-A14 G418r clones  
A 2.2 KB region of the plasmid pEAA613 containing kanMX::insE-A14 was PCR 
amplified from total DNA [42] isolated from revertant colonies (NATr, G418r) or non- revertant 
controls (NATr, G418s) using Phusion Hot Start II DNA polymerase (Thermo Fischer Scientific) 
and primers AO3879 (5’CTCGTTTTCGACACTGGATGGC) and AO3880 
(5’GCGTGAGCTATGAGAAAGCGC). Primer AO3838 
(5’TGGTCGGAAGAGGCATAAATTC) was used to sequence the PCR product in the region 
surrounding the homopolymeric A sequence.  
 
lys2-A14 reversion assay  
Independent colonies of EAY1365 (relevant genotype lys2-A14) containing the ARS-
CEN, MLH1 and ARS-CEN, PMS1 plasmids presented in Table 2.4 were inoculated into YPD 
liquid media, grown overnight at 30°C, and then plated onto LYS, HIS, LEU dropout and HIS, 
LEU dropout synthetic plates. These strains were analyzed for reversion to Lys+ as described 
previously [11, 41]. The 95% confidence intervals were determined as described by Dixon and 
Massey [45]. The Mann-Whitney U test [47] was performed to determine the significance of the 
differences in median reversion rates.  
 
5-fluoroorotic acid resistance assay  
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Resistance to 5-fluoroorotic acid (5-FOA) was measured in FY90, EAY4087 (mlh1' 
derivative of FY90), and haploid spore clones of YJS5885 using a protocol similar to Lang and 
Murray [48]. Single colonies from a synthetic complete media were grown overnight in 2 ml 
liquid synthetic complete media (0.7% yeast nitrogen base, 0.087% complete amino acid mix, 
2% dextrose); diluted 1:500 into synthetic complete media and grown in 5 ml for 2 days at 30°C 
with shaking. Appropriate dilutions were then plated onto 5-FOA (0.1% 5-FOA, 0.7% yeast 
nitrogen base, 0.087% amino acid mix without uracil, 0.005% uracil, 2% dextrose, 2% agar) and 
synthetic complete plates, and mutation rates were determined using previously published 
methods [11, 41, 44]. 95% confidence intervals were determined as described by Dixon and 
Massey [45]. Mann-Whitney U tests were performed using Prism (GraphPad Prism 7.00 for Mac 
OS X, GraphPad Software, La Jolla, California USA; www.graphpad.com) to determine the 
significance of the differences in median reversion rates [46, 47]. The URA3 open reading frame 
was PCR amplified from genomic DNA of independent 5- FOA resistant spore clones using 
Phusion Hot Start II DNA polymerase (Thermo Fischer Scientific) and primers AO1115 
(AGAAGAGTATTGAGAAGGGCAA) and AO3784 (TTAGTTTTGCTGGCCGCATC). 
Primers AO3156 (GGTGAAGGATAAGTTTTGACCATCAAAGAA) and AO3788 
(CTGGAGTTAGTTGAAGCATTAGGTC) were used to sequence the PCR product.  
 
Whole genome sequencing  
Single colonies of isolates, spore clones and transformants were grown overnight in 2 ml 
YPD media and genomic DNA was isolated using the YeaStar Genomic DNA kit (Zymo 
Research). DNA was barcoded using Illumina Nextera XT and high throughput DNA sequencing 
was performed on an Illumina NextSeq500 at the Cornell Biotechnology Resource Center, 
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achieving a 50-fold mean coverage. Sequences were aligned to the reference S288c genome 
sequence (SGD: https://www.yeastgenome.org/) using HISAT2 to create SAM (Sequence 
alignment map) files. SAM files were converted to binary version BAM files. BAM files were 
sorted and indexed, and duplicates were removed using SAMTools-1.7 
(http://samtools.sourceforge.net/). Aneuploidy plots (Figure 2.8 and 2.10) were constructed using 
a custom made script (provided by V.P. Ajith, IISER Trivandrum): read counts were tabulated 
for 5000 bp windows using the GenomicRanges and GenomicAlignments Bioconductor 
packages in a custom R-script. SnpEff was used to annotate variants using sequence information 
for YJS5845 and YJS5885 described in Peter et al. [36].  
 
Flow cytometry  
Cells were prepared using a protocol modified from Rosebrock [49]. Cells were grown 
overnight in rich medium, washed and fixed in 70% ethanol in -20°C for 24 hours. Fixed cells 
were washed, resuspended in 50 mM sodium citrate, pH 7.4 and allowed to rehydrate. RNase A 
(Thermo Scientific) was added to a final concentration of 0.2 mg/ml and incubated at 37°C 
overnight. Cells were then treated with Proteinase K (NEB) to a final concentration of 16 
units/ml at 37°C for 1 hour, sonicated for 10 sec at 30% power. Cells were then pelleted, 
supernatant was removed, and fresh 50 mM sodium citrate pH 7.4 was added, followed by 
staining of cells using Sytox Green at a final concentration of 1 μM. Flow cytometry was 
performed on BD FACS Aria at Cornell University flow cytometry core laboratory. YJS5885 
spore clones showed multiple peaks even after gating out cell clumps, therefore the peaks were 
sorted and visualized under the microscope to determine the composition of cells under each 
peak. Peak one had single cells and peak two had a combination of single cells and small budded 
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cells, peaks three and four had large budded cells or multiple budded cells. The population from 
last two peaks were removed during analysis, because they were present as cell clumps and were 
thus not a correct representation of the DNA content in each cell, using FlowJo 10.4.2 software. 
The unsorted cells were counted under the microscope to determine the fraction of single cells, 
small-budded cells and large budded cells. The buds with diameter less than half of mother cell 
were classified as small-budded cells [50].  
 
Data Availability  
Strains and plasmids are available upon request, and the entire DNA sequences of the 
MLH1 and PMS1 genes from 1011 isolates are presented in Bui et al. [15]. Supporting 
information contains all detailed descriptions of supplemental files. All wet lab experiments 
presented (lys2- A14 reversion, kanMX::insE-A14 reversion, 5-FOA resistance) were repeated on 
at least two separate days.  
Results  
Genotyping of yeast isolates containing incompatible cMLH1-kPMS1 combinations  
We identified among 1011 yeast isolates one clinical isolate (YJM523) that was 
homozygous and eighteen that were heterozygous for an S288c MLH1-SK1 PMS1 
incompatibility that confers a mutator phenotype in laboratory strains (Materials and Methods; 
Figure 2.1, 2.2; Table 2.1; [15]). This phenotype is abbreviated as cMLH1-kPMS1 and was 
assigned based on the amino acid at position 761 in MLH1 and 818/822 in PMS1. For YJM523, 
analysis of a derived spore clone (YJM555), and DNA sequencing and phylogeny analysis 
suggested that it is homothallic and homozygous for MLH1 and PMS1 sequence information 
(Table 2.2; [19]). Genetic analysis indicated that YJM555 is not a mutator but contains multiple 
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mutations that suppress and enhance the cMLH1-kPMS1 incompatibility [15, 21]. Of the 18 
isolates heterozygous for cMLH1-kPMS1 incompatibility, five are diploid, three of which can 
sporulate (Figure 2.2; Table 2.3). The remainder are triploid or tetraploid. Several tetraploids 
were genotyped (Table 2.1; Figure 2.4), showing a variety of cMLH1:kMLH1 genotypes (4:0, 
3:1, 2:2).   
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Figure 2.2: Isolates containing heterozygous MLH1-PMS1 genotypes predicted to form 
mutator spore progeny. Eighteen isolates were identified from the 1011 yeast genome project 
that are heterozygous for the MLH1 761 and/or PMS1 818/822 genotypes, and are predicted to 
yield incompatible spore progeny [15].   
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Table 2.3: Yeast isolates analyzed in this study 
 
Lab, standard, 
isolate ID Origin ploidy 
 SNPs, 
(singletons) 
spore 
form. 
(%) 
(n) 
% 3,4 
spore 
% 2 
spore 
% 
viable 
spores 
(tetrads) 
        
YJS5845, CIC, 
Ponton 11  
Human, mouth, 
Spain 2 68,564 (825) 
93 
(147) 53 39 20 (40) 
YJS5845 + CHR 
XIV    
96 
(174) 60 35 19 (39) 
YJS5885, CKN, 
CLI_19  
Human, feces, 
France 2  76,104 (955) 
57 
(139) 31 24 30 (28) 
YJM521  
Human clinical, 
CA, USA 2 53,947 (22) 
78 
(221) 69 5.9 94 (10) 
YJS4806, CFI, 
WLP013 Beer, UK 4* 
 nt   15 (10) 
YJS4810, CFN, 
WLP006 Beer, unknown 4* 
 nt   5.0 (10) 
YJS5882, CKK, 
CLI_16 
Human clinical, 
France 4 
 nt   72 (8) 
YJS5678, CBF, 
SD-15 Bakery, Italy 4* 
 nt   70 (10) 
YJS5512, BML, 
NCYC_2780 
Human clinical, 
Belgium 4* 
 nt   nt 
YJS4970, CGC, 
UCD_06-645 
Fruit, Davis, 
CA, USA 4 
 no 
spores 
   
 
19 of 1011 baker’s yeast isolates contain the incompatible MLH1-PMS1 genotype in 
heterozygous (18 isolates) or homozygous (YJM523) combinations (Bui et al. 2017). One isolate 
is triploid and 12 are tetraploid (six are shown here), two of which cannot sporulate. The 
remaining six are diploid, and the four diploid isolates that sporulate, YJS5845, YJS5885, 
YJM521, YJM523, all belong to the MR3 mosaic clade (113 members) that are admixed with 
ancestry from two or more populations. In the MR3 clade, the mean number of singletons was 
721 (+/-1150 SD, +/-108 SE, median = 163). The diploid isolates YJM521 [51] and YJS5845 are 
homothallic and YJS5885 appears to be functionally heterothallic (see text). The % of cells 
forming at least one spore (n is the cells examined) is shown under spore formation, and the 
distribution of these cells into 3,4 or 2 spore asci is shown, along with the % spore viability seen 
in dissected tetrads (n= number dissected). Our original stock of YJS5845 contained euploid and 
aneuploid (additional copy of Chr XIV) cells. The euploid and aneuploid isolates were analyzed 
for spore formation and viability separately. * Contains chromosomal aneuploidy [36]. nt, not 
tested.
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Figure 2.3: YJS5845, YJS5885, and spore clones have different colony sizes/growth 
properties. (A) YJS5845 was sporulated and then tetrad- dissected on minimal complete plates. 
Germinated spore clones were photographed after a 48-hr incubation at 30ºC . (B) YJS5845 and 
YJS5885 isolates, and representative spore clones, were struck to single colonies on YPD media 
and photographed after a 48-hr incubation at 30ºC.  
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Characterizing the yeast isolates that contain incompatible cMLH1-kPMS1 combinations  
Three heterozygous diploid clinical isolates (YJM521, YJS5845, YJS5885) displayed 
rapid vegetative growth and formed colonies from single cells on YPD plates in 24 hrs. They 
also showed a high efficiency of sporulation, with variable spore viability (20-94%) and spore 
clone growth (Figure 2.3; Table 2.3). At least one of the YJS5845 spore clones genotyped 
displayed what appeared to be invasive growth properties on YPD. We also saw some deviation 
from 1:1:1:1 for MLH1 and PMS1 genotypes in YJS5845 and YJS5885, which we had not seen 
in the high spore viability isolate YJM521 (Table 2.1). We sporulated some of the tetraploids 
with the goal of identifying homozygous incompatible spore clones. However, as shown in Table 
2.1 and Figure 2.4, such clones were not identified.  
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Figure 2.4: DNA sequence, as shown by chromatogram traces, of the MLH1 incompatibility site 
(bp 2282, Gly or Asp at amino acid 761) in the indicated isolates and spore clones.  
  
Genotyping at bp 2282 in MLH1 (G/D at amino acid 761) 
Fig S2
YJS5845 1:1 G:A
YJS4806 3:1 G:A
YJS4806 
spore clone
2:2 G:A
YJS4806 
spore clone
4:0 G:A
YJS4810 3:1 G:A
YJS5882 3:1 G:A
YJS5678 3:1 G:A
YJS5512 3:1 G:A
YJS4970 2:2 G:A
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The YJS5845, YJS5885 and YJM521 are all human clinical isolates, belong to an 
admixture clade, and have different geographic locations (Table 2.3). For MLH1, YJS5845 and 
YJS5885 contain the exact amino acid sequences for the S288c MLH1 allele on one chromosome 
and the exact amino acid sequences for the YJM521 MLH1 k-allele on the other chromosome 
(Table 2.2). For PMS1, YJS5845 and YJS5885 contain the exact amino acid sequences for the 
SK1 PMS1 allele on one chromosome. The other PMS1 bearing chromosome in both isolates 
contains the S288c PMS1 K818 allele; however, this chromosome contains unique variants for 
the two isolates (Table 2.2). YJM521 is homozygous for the MLH1- P271 suppressor allele 
(Table 2.2 and 2.4).  
Mutator phenotypes exhibited by incompatible S288c MLH1-SK1 PMS1 combinations of the 
YJM521, YJS5845 and YJS5885 isolates in the S288c strain background 
The incompatible combinations of MLH1 and PMS1 present in YJS5845, YJS5885, and 
YJM521 were tested for their ability to confer a mutator phenotype in the S288c background 
(Table 2.4). The incompatible combination from YJM521 was cloned; the incompatible 
combinations in YJS5845 and YJS5885 are represented by cMLH1-kPMS1 because the amino 
acid sequences are identical to the cMLH1-kPMS1 combination. The cMLH1-kPMS1 
combination representing YJS5845 and YJS5885 conferred an incompatible mutator phenotype 
(75-fold higher than compatible), while the cMLH1-kPMS1 combination from YJM521 
displayed a suppressed incompatible mutator phenotype (19-fold higher than compatible) that 
was expected because YJM521 is homozygous for the MLH1-P271 suppressor allele [43].   
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Table 2.4: Mutation rates in an S288c strain containing MLH1 and PMS1 genes 
combinations identical in amino acid sequence to those present in S288c, SK1, YJS5845, 
YJS5885, and YJM521. 
MLH1-PMS1 genotype Lys+ reversion rate (10-7), (95% CI) Relative rate (n) 
    
S288c-S288c, compatible 4.1 (1.7-13.8) 1 13 
S288c-SK1, incompatible 311 (111-919)** 75 16 
YJM521c-YJM521k 92 (78.4-690)* 22 29 
YJM521c-SK1 80 (47-182)* 19 15 
mlh1Δ, pms1Δ 45,300 (13,170-126,800)** 10,970 10 
    
EAY1365 (relevant genotype mlh1Δ::KanMX4, pms1Δ::KanMX4) was transformed with ARS-
CEN plasmids containing the MLH1 and PMS1 genes obtained from the indicated strains and 
isolates. Independent cultures (n) were examined for reversion to Lys+. Median mutation rates 
are presented with 95% confidence intervals, and relative mutation rates compared to the wild 
type strain are shown. Data for S288c-S288c compatible, S288c-SK1 incompatible, and mlh1', 
pms1' were reported previously [15]. Note that MLH1 open reading frames in YJS5845c and 
YJS5885c are identical to S288c MLH1 and the PMS1 open reading frames in YJS5845k and 
YJS5885k are identical to SK1 PMS1 (Table S2). 
*Significantly different from S288c-S288c, compatible (p < 0.01, Mann Whitney test) 
**Significantly different from S288c-S288c (p < 0.001, Mann Whitney test) 
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Spore clones from YJS5845 and YJS5885 display a wide range of mutator phenotypes, with 
MLH1-PMS1 genotype being the major contributor to mutation rate 
We examined the mutation rate in isolates and spore clone derivatives that had an 
approximately 100% efficiency of growth in YPD media containing geneticin when transformed 
with the in-frame plasmid pEAA611 (Figure 2.5). This was done to remove spore clones that 
were highly sensitive to aminoglycoside antibiotics (often observed in yeast isolates; [52, 53]). It 
is important to note that as a result of this analysis we assayed mutator phenotypes in roughly 
half of the spore clones obtained; the other half displayed poor efficiencies of plating on YPD 
media containing geneticin (Figure 2.5; Materials and Methods; no linkage was seen between 
efficiency of plating and MLH1, PMS1 compatible or incompatible genotypes). Using SNPeff 
(Materials and Methods), we confirmed the sequences of previously identified genes involved in 
antibiotic sensitivity, STP22 and PHO80, in YJS5845 and YJS5885 but did not find any 
disruptions or predicted deleterious alleles (Table 2.6; Ernst and Chan 1985; Wickert et al. 
1998).  
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Figure 2.5: Efficiency of plating of strains transformed with pEAA611, comparing growth on 
clon-NAT and clon-NAT + G418 plates. Representative images of EAY1369, EAY1370, 
YJM521, YJS5845 and YJS5885 isolates and YJS5885 spore clones are shown. 
 
  
NAT
YJM521
YJS5845
YJS5885
EAY1369
EAY1370
5885-2a (S)
5885-19a (R)
G418 + NAT
Fig S3
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Table 2.5: Reversion assay using the URA3 promoter-KanMX::insE-A14 plasmid. 
Strain or 
Isolate 
Genotype 
MLH1-
PMS1 
Incompatible/ 
Compatible 
rate* G418r (10-7), 
(95% CI), n 
rate** G418r (10-
7), (95% CI), n 
relative 
rate 
EAY1369 c-c C 5.2 (3.3-7.9), 15  1 
EAY1370 c-k I 57a (38-89), 19  11 
EAY1372 msh2' not applicable 9540a, c (6640-
24800), 10 
 1840 
YJS5845 c/k, c/k Parental (C/I) 2.6a, c (2.07-2.8), 16  0.50 
      
5845-7a k-c C 0.99b, d (0.56-1.1), 
10 
 0.19 
5845-16 k-k C 2.1a, c (1.6-2.7), 10  0.40 
5845-27a k-k C 2.1a, c (1.2-3.7), 10  0.41 
5845-35a k-k C 5.8c (3.1-14), 15  1.1 
5845-19a k-k C 6.0c (3.8-7.4), 15  1.2 
5845-22a k-k C 7.2c (5.2-9.4), 15  1.3 
      
5845-21a c-k I 2.7b, c (0.53-10), 16 0.38b, c (0.32-0.94), 
36 
0.51 
5845-20a c-k I 3.6c (0.9-8.4), 11  0.69 
5845-30a c-k I 16a, c (7.6-26), 16  3.2 
5845-19 c-k I 141a, c (86-320), 16  27 
5845-18a c-k I 330a, c (253-1300), 
10 
 64 
      
YJS5885 c/k, c/k Parental (C/I) 2.6b, c (1.4-6.5), 15  0.51 
      
5885-1a k-c C 0.74a, c (0.54-1.2), 
15 
 0.14 
5885-14a c-c C 1.1a, c (0.44-3.4), 10  0.21 
5885-20b k-c C 1.5a, c (1-1.6), 13  0.29 
5885-5b k-k C 1.6a, c (0.53-2.2), 15  0.31 
5885-10a k-k C 2.1a, c (1.2-3.5), 25 1.6a, c (0.65-2.6), 
34 
0.41 
5885-19b k-c C 2.5a, c (1.4-3.2), 25 1.4a, c (0.75-2.6), 
34 
0.48 
5885-15b c-c C 13a, c (8.6-18), 25 8.6b, c (5.8-13), 36 2.5 
5885-6a c-c C 62a (46-97), 10  12 
5885-9a c-k I 17a, c (11-23), 15  3.3 
5885-4b c-k I 24a, c (16-29), 15  4.6 
5885-16a c-k I 85a (37-222), 10  16 
5885-19a c-k I 86a (20-130), 10  17 
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Table 2.5 (continued) 
The isolates YJS5845 and YJS5885 and derived spore clones were transformed with pEAA613 
(ARS–CEN URA3 promoter-kanMX::insE-A14). 4 to 6 independent cultures of each transformant 
were examined for reversion to geneticin resistance as described in the Materials and Methods. 
Median mutation rates are presented with 95% confidence intervals, and relative mutation rates 
compared to EAY1369 (S288c compatible) are shown. n= number of independent repetitions. 
The genotype of the isolates and spore clones is presented with respect to the S288c (c) or SK1 
(k) amino acid position in amino acid 761 in Mlh1 and 818/822 in Pms1 (Figure 2.2). 
Heterozygous genotypes are indicated by the “/”. In this nomenclature c-c =S288c genotype, k-k 
= SK1, k-c = ancestral, and c-k = incompatible. **For 5845-21a, 5845-41a, 5885-10a, 5885-15b 
and 5885-19b spore clones there were 4 (of 8 tested), 4 (of 8 tested), 2 (of 7 tested), 2 (of 7 
tested), 2 (of 6 tested) transformants, respectively, that gave low reversion rates (see Materials 
and Methods for details). The rate of reversion to G418r in this column include the data from the 
low reversion transformants; however, the column marked with * does not include these 
transformants, nor does the relative rate column. a Significantly different from EAY1369 (p 
<0.001, Mann–Whitney test); b Significantly different from EAY1369 (p <0.01, Mann–Whitney 
test); c Significantly different from EAY1370 (p <0.001, Mann–Whitney test); d Significantly 
different from EAY1370 (p <0.01, Mann–Whitney test). YJS5845 compatible and incompatible 
spore clones (p <0.001) and YJS5885 compatible and incompatible spore clones (p <0.001) are 
significantly different from each other (Mann-Whitney test). 
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Table 2.6: Analysis of HO, PHO80 and STP22 genes in YJS5845 and YJS5885 for variants 
using SnpEff.  
     
Gene Name Mutation Type of 
mutation 
Amino acid 
change 
Predicted effect of missense 
mutation by SnpEff 
YJS5845     
HO gene in 
Chromosome IV 
1756T>C missense Cys586Arg Deleterious 
1740C>T synonymous Asn580Asn  
1722T>C synonymous His574His  
1718C>T missense Pro573Leu Tolerated 
1710C>T synonymous Val570Val  
1635C>T synonymous Gly545Gly  
1214C>T missense Ser405Leu Tolerated 
1059T>C synonymous Val353Val  
1026C>A synonymous Gly342Gly  
789A>G synonymous Leu263Leu  
667A>G missense Ser223Gly Tolerated 
565G>A missense Ala189Thr Tolerated 
369G>A synonymous Arg123Arg  
     
PHO80 in 
Chromosome XV 
21A>C missense Glu7Asp Tolerated 
111G>A synonymous Val37Val  
    
STP22 in 
Chromosome III 
1000C>A missense Gln334Lys Tolerated 
546A>G synonymous Pro182Pro  
528T>C synonymous Asn176Asn  
525G>A synonymous Gln175Gln  
492C>G synonymous Pro164Pro  
36G>A synonymous Ala12Ala  
YJS5885     
HO gene 
Chromosome IV 
1740C>T synonymous Asn580Asn  
1710C>T synonymous Val570Val  
1635C>T synonymous Gly545Gly  
1424T>A missense Leu475His Tolerated 
1214C>T missense Ser405Leu Tolerated 
667A>G missense Ser223Gly Tolerated 
369G>A synonymous Arg123Arg  
     
PHO80 gene in 
Chromosome XV 
21A>C missense Glu7Asp Tolerated 
111G>A synonymous Val37Val  
266C>T missense Ser89Phe Tolerated 
375A>G synonymous Thr125Thr  
739C>T missense Pro247Ser Tolerated 
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Table 2.6 (continued) 
 
Gene Name Mutation Type of 
mutation 
Amino acid 
change 
Predicted effect of missense 
mutation by SnpEff 
YJS5885     
     
STP22 gene in 
Chromosome III 
1000C>A missense Gln334Lys Tolerated 
528T>C synonymous Asn176Asn  
525G>A synonymous Gln175Gln  
492C>G synonymous Pro164Pro  
123T>A missense Asn41Lys Tolerated 
78C>A missense Asn26Lys Tolerated 
36G>A synonymous Ala12Ala  
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To measure mutation rate, isolates and spore clones were transformed with pEAA613, a 
mutation rate reporter vector that measures reversion of an A14 sequence inserted into the 
KANMX gene (Figure 2.7A). We confirmed that in these isolates and spore clones resistance to 
G418 resulted in frameshift mutations in the A14 sequence that restored the KANMX reading 
frame (Figure 2.6). Mutation rates in EAY1369 (compatible) and EAY1370 (incompatible) 
controls were highly reproducible when measured with independent transformations and 
repetitions on different days. YJS5885 and YJS5845 were non-mutators but yielded spore clones 
with a range of mutation rates in a DNA slippage assay that varied over ~340-fold (Table 2.5; 
Figure 2.7). Mutation rates of incompatible spore clones were significantly different from 
compatible spore clones in both YJS5845 and YJS5885 as determined by Mann- Whitney U test 
(p<0.001, Figure 2.7B; Table 2.5). This indicates that the cMLH1-kPMS1 genotype is the major 
contributor to high mutation rates, though there were examples where spore clones compatible  
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Figure 2.6: Sequencing analysis of G418 resistant revertants and sensitive control colonies. 
The homopolymeric A-runs in isolates and spore clones transformed with pEAA613 were 
sequenced (Materials and Method). The sequencing data from G418 resistant (top) and sensitive 
(bottom) colonies are presented. Only G418 resistant colonies displayed A14 to A13 frameshift 
mutations.   
EAY1370 G418r, NATr
YJS5845 G418r, NATr
YJS5885 G418r, NATr
5885-1a G418r, NATr
5885-9a G418r, NATr
5885-3a G418r, NATr
5845-27a G418r, NATr
5845-21a G418r, NATr
5885-5a NATr, G418s
5885-9a NATr, G418s
5845-19 NATr, G418s
Controls, NATr, G418s
Revertants, G418r, NATr
Fig S4
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Figure 2.7: Mutation rate assay. (A) Isolates and spore clones were transformed with 
pEAA613, an ARS-CEN, URA3 promoter-KanMX::insE-A14 plasmid used to measure mutation 
rates in natural yeast isolates that contains a NatMX selectable marker and a frameshift reporter 
in which the insE-A14 sequence from Tran et al. (1997) was inserted immediately after 
methionine 17 in the KanMX open reading frame. pEAA611 is in-frame for KanMX whereas 
pEAA613 contains a +1-frameshift mutation that disrupts KanMX function. Frameshift mutation 
events (e.g., a 21 deletion in the homopolymeric A run) are detected on YPD plates containing 
clonNAT and geneticin (G418). Spore clones were first screened for efficiency of plating in 
G418 by transforming with pEAA611 that contains KanMX::insE-A10. (B) Mutation rates of 
YJS5845, YJS5885, and their spore clones in a G418 reversion assay relative to the compatible 
S288c-derived strain EAY1369. The parental isolates YJS5845 and YJS5885 are in light blue, 
compatible spore clones are in blue, incompatible spore clones are in green, the EAY1369 
compatible laboratory strain is in black, and the EAY1370 incompatible laboratory strain is in 
red. Compatible and incompatible spore clones from YJS5845 and YJS5885 were significantly 
different from each other, as determined by Mann–Whitney U-test (* P , 0.001). The spore 
clones are named as follows: 1, 5845-7a; 2, 5845-16; 3, 5845-27a; 4, 5845-35a; 5, 5845-19a; 6, 
5845-22a; 7, 5845-21a; 8, 5845-20a; 9, 5845-30a; 10, 5845-19; 11, 5845-18a; 12, 5885-1a; 13,  
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Figure 2.7 (continued) 
5885-14a; 14, 5885-20b; 15, 5885-5b; 16, 5885-10a; 17, 5885-19b; 18, 5885-15b; 19, 5885-6a; 
20, 5885-9a; 21, 5885-4b; 22, 5885-16a; and 23, 5885-19a   
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for MLH1-PMS1 showed mutation rates similar to that observed in incompatible strains, 
and vice-versa (for example, see analyses of spore clones 5885-6a and 5845-21a in Figure 2.7 
and Table 2.5). Several compatible and incompatible spore clones had significantly different 
mutation rates compared to EAY1369 (laboratory compatible) and EAY1370 (laboratory 
incompatible). As shown in Figure 2.7 and Table 2.5, up to a seven-fold lower mutation rate was 
seen between compatible spore clones and strain EAY1369 and up to a six-fold higher mutation 
rate was seen between incompatible spore clones and strain EAY1370. These data indicate that 
modifiers are present in the isolates that impact mutation rate (Figure 2.7B; Table 2.5).  
YJM521 displayed poor efficiency of plating with pEAA611 (a plasmid containing an in- frame 
homopolymeric A10 run in the KANMX gene; Figure 2.5). We also found that the previously 
characterized isolate YJM555 [15], a spore clone of YJM523, also displayed inefficient plating 
with pEAA611. Thus, it was not possible to accurately measure mutation rates in these isolates 
or their spore clones using pEAA613 (Table 2.5). However, YJM521 is unlikely to be a strong 
mutator because it is homozygous for the MLH1-P271 suppressor allele (Table 2.4), and 
YJM555 was shown not to be a mutator using a 5-FOA based reversion assay [21], and had 
acquired suppressor mutations [15].  
We also measured the rate of resistance to 5-fluoroorotic acid (FOAr) in haploid 
YJS5885 spore clones (see FACS analysis below). This resistance results primarily from 
recessive base substitution mutations in the URA3 gene that confer loss of function [48]. Zeyl 
and DeVisser [54] observed a 152-fold difference in the rate of 5-FOAr between wild-type and 
msh2 haploid strains and Thompson et al. [9] reported a 10-fold difference between wild type 
and mutator strains. We observed a 20-fold difference between the haploid wild type in the 
S288c background (7.9 x 10-8) and an mlh1' derivative (1.6 x 10-6; Table 2.7). Interestingly, we 
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observed a thirteen-fold range in mutation rate in a set of seven YJS5885 spore clones (4.8 x 10-
8 to 6.4 x 10-7; Table 2.7). We sequenced the URA3 open reading frame from thirteen 5-FOA 
resistant colonies (Table 2.7). Ten independent URA3 mutations were detected, three missense, 
five nonsense, and two single-base deletions. There were no mutations identified in three 
mutants. Similar percentages of 5-FOAr colonies containing mutations in the URA3 gene were 
seen in our study (77%) and an earlier one (87%; [48]). The rank order of mutation rates for the 
YJS5885 spore clones in the 5- FOAr and kanMX::insE-A14 reversion assays did not precisely 
correlate (Table 2.5; Table 2.7). This result is not surprising because the two assays measure 
different mutation spectra, with the kanMX::insE-A14 reversion assay detecting DNA slippage 
events in homopolymeric repeats, and the 5-FOAr assay detecting primarily base substitutions 
[48].  
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Table 2.7: Analysis of resistance to 5-FOA in YJS5885 spore clones. 
 
Strain or spore  Incompatible/ Compatible Rate 5-FOA
r (10-7), (95% C.I.), n Relative rate 
FY90 C 0.79 (0.26-2.6), 22 1 
EAY4087 (mlh1') Not applicable 16a (9.5-18), 20 20 
5885-1a C 1.9b (0.72-5.2), 15 2.4 
5885-14a C 0.98b (0.53-2.1), 15 1.2 
5885-15b C 0.48b (0.37-3.2), 15 0.61 
5885-6a C 0.68b (0.32-1.5), 15 0.86 
5885-9a I 6.0a, b (4.7-9.7), 15 7.6 
5885-16a I 1.5b (0.92-1.9), 15 1.9 
5885-19a I 6.4a, b (2.9-7.9), 15 8.1 
 
The rate of resistance to 5-FOA, presented with 95% confidence intervals (95% C.I.), was 
determined for n independent cultures of FY90 and the indicated spore clones of YJS5885 as 
described in the Materials and Methods. The URA3 open reading frame (ATG =+1) was 
sequenced from 7, 2, 1, 1, 1 and 1 independent 5-FOAr colonies from 5885-9a, 5885-15b, 5885-
1a, 5885-14a, 5885-16a, and 5885-19a, respectively. a Significantly different from FY90 
(p<0.001, Mann-Whitney test); b Significantly different from EAY4087 (p<0.001, Mann-
Whitney test). YJS5885 compatible and incompatible spore clones are significantly different 
from each other (p<0.001, Mann-Whitney test). 
 
10 of the 13 spore clones contained single mutations in URA3, with the following distribution: 
5885-9a: Two missense (bp287,A>T; bp542, G>A), One nonsense (bp577, G>T), Two single  
nucleotide deletions (bp178, A deleted; bp629, G deleted), no changes in ORF for two 5-
FOAr mutants. 
5885-15b: One missense (bp205, T>C), one nonsense (bp345 G>A). 
5885-1a: One nonsense (bp223 A>T). 
5885-14a: One nonsense (bp593 T>A). 
5885-16a: No changes in ORF for one 5-FOAr mutant.  
5885-19a: One nonsense (bp310 C>T). 
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YJS5845 and YJS5885 spore clones are diploid and haploid, respectively  
Wild yeasts are primarily homothallic, indicating that daughter cells can switch mating 
type and mate with mother cells [55, 56]. YJM521 and YJM523 are homothallic [51] and we 
hypothesized that YJS5845 is also homothallic because it yielded spore clones (12 of 15) that 
can sporulate (Table 2.8). It appears that YJS5885 is functionally heterothallic because most of 
its spore clones (24 of 26) were unable to sporulate. We tested the ploidy of YJS5845 and 
YJS5885 spore clones for which we measured mutation rates by flow cytometry and showed that 
YJS5845 spore clones were diploid while those of YJS5885 were haploid (Figure 2.8A; Figure 
2.9). There are no disruptions in the open reading frame of the HO gene, which codes for the 
endonuclease involved in mating type switching in both YJS5845 and YJS5885 ([57]; Table 
2.6). However, there is a predicted deleterious variant in the HO gene of YJS5845 but not in 
YJS5885 (Table 2.6). To determine if defects in sporulation correlated to growth deficiency or 
defects  in mitochondria (normal mitochondrial function is necessary for meiosis; [58], spore 
clones.   
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Figure 2.8: Ploidy of isolates and spore clones. (A) Representative flow cytometry plots of 
YJS5845 [59], YJS5885 (right), and derived spore clones. All spore clones of YJS5845 and 
YJS5885 tested were diploid and haploid, respectively. The black arrows show the position of 
1n, 2n, and 4n DNA content. Inset shows percentage of single cells, small-budded cells, and 
large-budded cells assessed by light microscopy. (B) Whole-genome sequencing was performed 
for YJS5845 and spore clones (Materials and Methods). YJS5845, and spore clones 5845-18a 
and 5845-28b, displayed aneuploidy for chromosomes (Chr) XIV, XI, and I, respectively.  
  76 
 
Figure 2.9: Flow cytometry of spore clones. Spore clones of YJS5845 and YJS5885 were 
prepared for flow cytometry as described in the Materials and Methods. YJS5845 derived spore 
clones were diploid and YJS5885 derived spore clones were haploid. The black arrows show the 
position of 1n, 2n, and 4n DNA content. Inset shows the percentage of single cells, small budded 
and large budded cells in the indicated samples.  
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Table 2.8: Sporulation and lactate growth phenotype     
Spore 
clone Sporulation 
Lactate+ 
or -  
Spore 
clone Sporulation 
Lactate + 
or - 
5885-1a - +  5845-19a - - 
5885-6a - +  5845-22a + + 
5885-10a - -  5845-27a + + 
5885-20b - +  5845-7a + + 
5885-5b - +  5845-28b + + 
5885-15b - -  5845-29a + + 
5885-14a - +  5845-41a - - 
5885-19b - -  5845-16 + + 
5885-6b - +  5845-35a poor growth- few dyads + 
5885-5a - +  5845-18a + + 
5885-11a - +  5845-21a - + 
5885-12a - -  5845-20a + + 
5885-18a - -  5845-30a + - 
5885-9a - -  5845-19 + + 
5885-4b - +  5845-36b + NT 
5885-19a - -     
5885-16a - -     
5885-3a - +     
5885-12b - -     
5885-1b - NT     
5885-2a - NT     
5885-4a - NT     
5885-7a + NT     
5885-8a - NT     
5885-13a - NT     
5885-17a + NT     
Spores were patched on sporulation media and incubated at 30qC for 6 days after which they 
were examined for evidence of sporulation by light microscopy. Any samples with dyads, triads 
and tetrads were marked as being able to sporulate (+). Spores were also patched on YP-lactate 
media and scored as able to grow or not (Lactate+ or -) after 4 days in 30qC. NT: not tested  
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from YJS5845 and YJS5885 were analyzed for their ability to grow on media containing lactate 
as a carbon source. Three of fourteen YJS5845 spore clones and nine of nineteen YJS5885 spore 
clones failed to grow with lactate as a carbon source (Table 2.8). This explains why two of the 
YJS5845 spore clones were unable to sporulate, but we believe that YJS5885 is functionally 
heterothallic because its spore clones did not diploidize (Figure 2.8A and 2.9).  
Spore clones from saturated cultures were prepared for flow cytometry and subsequently 
examined by light microscopy to determine the populations of single, small budded and large 
budded cells in each sample. We observed that YJS5885 spore clones had a higher proportion of 
large budded cells (34-87% large budded cells as compared to <1% large budded cells in the 
isolate YJS5885; Figure 2.8A and 2.9) suggesting a possible activation of a G2/M checkpoint or 
a cell division defect. Some cells of spore clones were much larger than the cells from the 
original isolate (5885-9a, 20b, 5b), which might be due to higher DNA content in the spore 
clones or the possible defects outlined above. Spore clones of YJS5845 were primarily single 
unbudded cells and appeared similar to the parental isolate.  
 
Spore clones of YJS5845 display chromosome gain and loss  
Whole genome sequence analyses of YJS5845 and YJS5885 and their spore clones 
indicated that most of the spore clones are euploid (Figure 2.8B and 2.10). Interestingly, 
YJS5845 and two of 16 spore clones analyzed, 5845-18a and 5845-28b, displayed aneuploidy, 
with gains of a chromosome in YJS5845 (XIV) and 5845-18a [60], and a loss of a chromosome 
in 5845-28b (I). The YJS5845 stock that we obtained is a mixture of euploid and aneuploid cells 
(trisomy in chromosome XIV that contains PMS1) as determined by sequencing the PMS1 gene 
from several single colonies struck out from our original stock. Based on the heterozygosity in 
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the PMS1 sequence, we determined that of the 14 single YJS5845 colonies sequenced for PMS1, 
six had three copies (indicating aneuploidy) and eight had two copies of PMS1 (indicating 
euploidy). However, the sporulation efficiency and viability of euploid and aneuploid YJS5845 
were very similar (Table 2.3). The majority of the spore clones (except for 5845-7a, 16, 19) were 
isolated from the euploid YJS5845. YJS5885 is euploid and all spore clones derived from 
YJS5885 were also euploid (Figure 2.10).  
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Figure 2.10: Ploidy of YJS5845 and YJS5885 isolates and their spore clones. Whole genome 
sequencing is presented for YJS5845, YJS5885 and derived spore clones (Materials and 
Methods). The entire set can be found in Figure 2.8 and Figure 2.10. 
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Figure 2.10 (continued) 
 
  
Fig S6
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Discussion  
Spore clones of human clinical isolates yield a wide range of mutator phenotypes  
Mutator phenotypes can be challenging to analyze in natural isolates because they lack 
genetic markers, display differences in growth, show colony variation, and can have differential 
resistance to antibiotics. We overcame these hurdles to measure mutation rates in YJS5845 and 
YJS5885 isolates and their spore clone derivatives using a recently developed frameshift 
mutation reporter. We found that while the isolates themselves were non-mutators, they 
sporulated at high efficiency and their spore clones displayed a wide range of mutation rates, 
with a 340-fold difference between the lowest and highest mutator using a DNA slippage assay. 
cMLH1-kPMS1 incompatibility was the major contributor of the high mutation rate (Figure 2.7; 
Table 2.5). This study provides a practical and efficient strategy to characterize the phenotypic 
properties of human clinical yeast isolates. Other strategies such as bottleneck analysis of large 
numbers of independent isolates are also possible but are time consuming, and would require a 
significant effort to analyze a large amount of whole genome sequencing data.  
Opposing forces of genetic drift and natural selection ensure that most individuals in a 
population evolve to a basal non-zero mutation rate (reviewed in [61]). For the natural isolates 
analyzed in this study, we hypothesize that stress can induce sporulation, giving rise to 
individuals that display high deviations from the basal mutation rate. Under unpredictable and 
changing stress conditions in the human host, it is likely to be valuable to produce spores with a 
broad range of mutation rates that will ensure population survival, but such a range might not be 
optimal for individual cells. Spore clones with a high mutation rate might rapidly gain beneficial 
mutations but will also acquire deleterious mutations. Thus, having a range of mutation rates 
gives the population an opportunity to survive changing stress conditions. To prevent long-term 
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fitness costs these strains can either acquire suppressor mutations to become non-mutators or 
mate back with the compatible strains or outcross to become diploid non-mutators. The 
compatible mutants surviving stress would also have a higher mutation rate, but it is reasonable 
to assume that diploids resulting from mating of compatible and incompatible spore clones 
would have complementary recessive mutations and thus a non- mutator phenotype (as seen for 
the low spore viability in YJS5845 and YJS5885).  
Outcrossing with different isolates is thought to occur at a low frequency in the wild, 
once in every 50,000 generations [13, 62]. Stressful environments likely influence this rate, with 
levels estimated to be as high as one in every hundred to one in every two generations [63]. 
While such estimates are valuable, we hypothesize that the YJS5845 and YJS5885 isolates 
sporulated in stress conditions could yield mutator clones that are capable of mating with 
siblings, and thus not require outcrossing, to become compatible.  
 
Modifiers of incompatibility genotypes in clinical isolates  
The mutation rates of compatible and incompatible spore clones of YJS5845 and 
YJS5885 vary significantly from their corresponding laboratory strains (Figure 2.7; Table 2.5). 
This finding indicates the presence of enhancers and suppressors of mutation rate in the YJS5885 
and YJS5845 isolate backgrounds. Previously we identified both intragenic (MLH1-P271; [43]) 
and extragenic modifiers [15] of the cMLH1-kPMS1 incompatibility. In the case of the 
homozygous incompatible spore clone, YJM555, we observed what appeared to be multiple 
intergenic modifiers of the cMLH1-kPMS1 incompatibility [15, 21].  
Is there evidence for SNPs in MLH1 conferring a mutator phenotype or acting as intragenic 
modifiers of the cMLH1-kPMS1 incompatibility? 107 of the 1011 yeast isolates analyzed by Bui 
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et al. [15] display heterozygosities in the MLH1 and PMS1 genes. This information, and the fact 
that the yeast MLH1 gene has been extensively mutagenized through alanine-scanning, random 
mutagenesis, and site-specific mutagenesis (both in known domains and in homology modeling 
to HNPCC alleles; see Table 2.9) encouraged us to determine if any MMR alleles exist in 
heterozygous isolates that could confer a deleterious phenotype. As shown in Tables 2.9, we 
mapped heterozygosities present in 107 (including a newly identified one) isolates onto the 
MLH1 structure-function map and found that some cluster to regions in MLH1 predicted to 
affect function. These observations provide support for the idea that mutators in yeast grown in 
stressful conditions could be obtained through incompatibilities as well as the presence of 
recessive deleterious alleles.  
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Table 2.9: Assigning MLH1 polymorphisms found in heterozygous genotypes onto the 
MLH1 structure-function map.  
 
A structure function map for MLH1 was created from an analysis of MLH1 alanine scan and site-
specific mutations, and mlh1 alleles generated based on homology to HNPCC mutations [64-72]. 
Alleles that conferred a mutator phenotype in a variety of reporter assays are shown. In MLH1, 
amino acids 1-335 is referred to as that N-terminal/ATP binding domain, 335-509 as the linker 
domain, and 510-769 as the C-terminal interaction domain [73].  
  
 
mlh1 allele (Reference) Amino acid position: isolate(s) with heterozygous genotype 
  
N-terminal/ATP binding  
I22T [64] 22-ILE/LEU: APL, CFI, CFN 
  
Linker [40]  
R390A,K391A  391-LYS/ASN: BHL, BMQ 
K393A,R394A [40]  393-LYS/GLU: CPN, CPR 
R401A,D403A  402-ILE/LEU: ASN, BGB, BGI, BGM, BGS 
  
C-terminal interaction [40]  
E603A,D605A,E606A  605-ASP/ASN: BHL, BMQ 
K648A,K650A  
650-LYS/THR: ADL, AKT, BFE, BFG, BFM, BML, BMM, BTD, 
BTE, CKK, CKS, CLA 
E680A,D681A,E682A  681-ASP/ASN: CPN, CPR 
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Yeast growing in a human environment are likely to encounter multiple stresses  
Human clinical isolates of the fungal pathogen Cryptococcus have been identified that 
display a mutator phenotype due to mutations in the MSH2 mismatch repair gene [32, 33]. The 
authors of these studies suggest that pathogens undergo a significant change in environment 
when entering a human host and that challenges specific to the human host, such as survival in 
the presence of antifungals, provide an adaptive advantage for Cryptococcus isolates that are 
mutators [32, 33]. In a human environment S. cerevisiae is likely to deal with challenges that are 
analogous to those faced by Cryptococcus, including growth at high temperature and exposure to 
fungicides. In fact, several causative alleles were identified in clinical and laboratory yeast 
strains that provide growth advantages at high temperature [74, 75]. As summarized in the 
Introduction, many human clinical isolates of S. cerevisiae are mosaics (including YJS5845 and 
YJS5885) that contain a mixture of alleles from different subpopulations [16, 19, 21, 76].  
Our study of YJS5845 and YJS5885 highlights how isolates can adapt to stressful human 
environments. The incompatible alleles do not confer a mutator phenotype in these heterozygotes 
but may provide an advantage as they appear to be poised to adapt to stress through the variable 
mutation rates in the progeny (Figure 2.7B, Table 2.5). This variation in mutation rates is due to 
the presence of modifiers in the background of these strains as a consequence of being 
heterozygotes. Furthermore, one of the isolates and its spore clones show evidence of losing and 
gaining chromosomes at high frequency (Figure 2.8B), which could also be highly beneficial for 
rapid adaptation in the clinical setting by affecting mutation rates. Variance in mutation rate, at 
least for baker’s yeast, is likely to provide only a transient advantage due to fitness costs, and 
changes in environment would need to be accompanied by the acquisition of suppressor 
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mutations, mating with nearby spore clones, return to euploidy, or by outcrossing to become 
non-mutators.  
 
Ploidy, mutation rate and adaptation  
Chromosome aneuploidy and increases in ploidy have been shown to provide faster 
routes to adaptation by increasing mutation rate and increasing the likelihood of gaining a 
beneficial mutation [22-26, 77]. For example, compared to haploid and diploid baker’s yeast, 
tetraploid yeasts display more rapid adaptation, suggesting that increased ploidy impacts the rate 
of adaptation by providing a broad spectrum of adaptive mutations [29, 78]. Consistent with this 
observation, diploid mutators display a growth advantage over diploid and haploid non-mutators 
and haploid mutators in several stress conditions [9]. In our study we identified both haploid 
(YJS5885 derived) and diploid (YJS5845 derived) spore clone progeny, suggesting that ploidy 
may also play a role in regulating mutation rates of spore clones.  
Zhu et al. [20, 26] analyzed 132 clinical isolates of S. cerevisiae by whole genome 
sequencing and found that roughly one third had higher levels of ploidy (3n and 4n genome copy 
number), one quarter had partial chromosome copy-number variations and one third were 
aneuploid. We observed that our YJS5845 stock consisted of a mix of euploid and aneuploid 
cells. Furthermore, euploid YJS5845 yielded aneuploid spore clones, either through meiotic or 
mitotic chromosome segregation defects (Figure 2.8B). Interestingly, YJS5845 belongs to an 
admixture clade; thus, it is reasonable to assume that the chromosome segregation defects seen in 
this isolate are due to incompatibilities in processes involving a large number of components. 
While we do not have direct evidence that the aneuploidy seen in YJS5845 impacts mutation 
rate, work from the studies referenced above suggest that it is likely to play a significant role.   
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CHAPTER 3 
 
 
Purification of yeast and mouse Mlh1-Mlh3 complexes; biochemical analysis of yeast Mlh1-
mlh3 separation of function complexes and initial purification of mouse Mlh1-Mlh3. 
 
 
This work is a part of a study that was published in PLoS Genetics [1] and bioRxiv [2]. 
Appendix A represents a new protocol for purification of yeast Mlh1-Mlh3 
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Abstract  
Mlh1-Mlh3 is an endonuclease hypothesized to act in meiosis to resolve double Holliday 
junctions into crossovers. It also plays a minor role in eukaryotic DNA mismatch repair (MMR). 
To understand how Mlh1-Mlh3 functions in both meiosis and MMR, we analyzed in baker’s 
yeast 60 new mlh3 alleles. Five alleles specifically disrupted MMR, whereas one (mlh3-32) 
specifically disrupted meiotic crossing over. Mlh1-mlh3 representatives for each class were 
purified and characterized. Both Mlh1-mlh3-32 (MMR+, crossover-) and Mlh1- mlh3-45 
(MMR-, crossover+) displayed wild-type endonuclease activities in vitro. Msh2- Msh3, an MSH 
complex that acts with Mlh1-Mlh3 in MMR, stimulated the endonuclease activity of Mlh1-mlh3-
32 but not Mlh1-mlh3-45, suggesting that Mlh1-mlh3-45 is defective in MSH interactions. My 
observations reveal the importance of protein-protein interactions in regulating the enzymatic 
activity of Mlh1-Mlh3 protein complex. As part of this work, I also developed a strategy to 
purify the mouse Mlh1-Mlh3 complex and demonstrate that both the wild type and endonuclease 
active site mutant complexes can be purified as heterodimers.  
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Introduction  
During mismatch repair (MMR), insertion/deletion and base-base mismatches that form 
as the result of DNA replication errors are recognized by MutS homolog (MSH) proteins, which 
in turn recruit MutL homolog (MLH) proteins to form ternary complexes containing mismatched 
DNA, MSH factors, and MLH factors. These interactions result in the recruitment of 
downstream excision and resynthesis proteins to remove the error [3]. In S. cerevisiae repair of 
insertion deletion loops greater than one nucleotide in size primarily involves the MSH 
heterodimer Msh2-Msh3 and the MLH heterodimer Mlh1-Pms1 [3]. The MLH heterodimer 
Mlh1-Mlh3 has been shown to play a minor role in this process and can partially substitute for 
Mlh1-Pms1 in Msh2-Msh3-dependent MMR [4-6]. However, Mlh1-Mlh3 has been shown to 
play a major role in meiotic crossing over [7-10]. Accurate chromosome segregation in Meiosis I 
in most eukaryotes requires reciprocal exchange of genetic information (crossing over) between 
homologs [11-14]. Failure to achieve at least one crossover (CO) per homolog pair results in 
homolog nondisjunction and the formation of aneuploid gametes. Errors in meiotic chromosome 
segregation are a leading cause of spontaneous miscarriages and birth defects [15].  
Mlh1-Mlh3 is an endonuclease that nicks circular duplex DNA in vitro, and Mlh1-mlh3-
D523N is defective in endonuclease activity [16, 17]. This activity is dependent on the integrity 
of a highly conserved (DQHA(X)2E(X)4E) metal binding motif found in Mlh3. Previous work 
demonstrated that a point mutation within this motif (mlh3-D523N) conferred mlh3Δ- like 
defects in MMR and crossing over. These included a mutator phenotype, a decrease in spore 
viability to 70% (from 97% in wild-type), and a two-fold reduction in genetic map distances [8].  
Approximately 200 double strand breaks (DSBs) are induced throughout the genome in a 
S. cerevisiae cell in meiotic prophase, of which ~90 are repaired to form COs between 
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homologous chromosomes, with the rest repaired to form noncrossovers (NCOs; [18-20]). In this 
pathway a DSB is resected, resulting in the formation of 3’ single-strand tails. One of these tails 
invades the other homolog and creates a single-end invasion intermediate (SEI). A second 
invasion event initiating from the SEI, known as second-end capture, can re-anneal and ligate to 
the other side of the DSB resulting in the formation of a double Holliday junction (dHJ). The 
dHJ can be acted upon by Holliday junction (HJ) resolvases to form CO and NCO products. In 
baker’s yeast the majority of COs are formed through an interference-dependent CO pathway 
(class I COs) in which the vast majority of dHJs are resolved to form COs in steps requiring the 
ZMM proteins Zip1-4, Mer3, and Msh4-Msh5 as well as the Sgs1-Top3-Rmi1 (STR) 
helicase/topoisomerase complex, Mlh1-Mlh3, and Exo1 [10, 21-28]. These steps are biased to 
resolve the two junctions present in the dHJ so that the resulting product is exclusively a CO. 
Interestingly, Exo1’s role in maintaining wild-type levels of crossing over is independent of its 
catalytic activity, suggesting a structural role for this pro- CO factor [28]. Consistent with the 
above observations, Msh4-Msh5, STR, Exo1 and Zip3 have all been shown to interact with one 
another and/or with Mlh1-Mlh3 [29]. 
Genetic and physical studies summarized below support a major role for Mlh1-Mlh3 in 
promoting meiotic CO formation in the interference-dependent CO pathway. 1. Genetic studies 
performed in yeast showed that mlh1 and mlh3 mutants display approximately two-fold 
reductions in crossing over [7, 30, 31]. 2. There are several factors that can resolve dHJs into 
COs in yeast using different pathways. This involves the endonucleases Mlh1-Mlh3, Mus81-
Mms4, Yen1, and Slx1-Slx4 [7, 8, 10], with Yen1 and Slx1-Slx4 acting in cryptic or backup 
roles. When all four factors were removed, crossing over was reduced to very low levels; 
however, in an mms4 slx4 yen1 triple mutant, in which Mlh1-Mlh3 is maintained, relatively high 
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CO levels (~70% of wild-type levels) were observed, suggesting that Mlh1-Mlh3 is the primary 
factor required for CO resolution in the interference-dependent CO pathway [10]. 3. MLH1 and 
MLH3 play critical roles in mammalian meiosis [32, 33]. For example, mlh3-/- mice are sterile 
with an 85–94% reduction in the number of COs; germ cells in these mice fail to maintain 
homologous pairing at metaphase and undergo apoptosis [32, 34].  
Much remains to be understood on how biased resolution of dHJs in the interference- 
dependent pathway is achieved. A working model, supported by genetic and molecular studies, is 
that the STR complex and a subset of ZMM proteins process and interact with DSB repair and 
SEI intermediates to create a dHJ substrate that can be resolved by the Mlh1-Mlh3 endonuclease 
and Exo1 to form primarily COs [7-10, 17, 25, 27, 28, 31, 35-41]. In this model, the biased 
cleavage of a dHJ suggests coordination between the two junctions that would likely require 
asymmetric loading of meiotic protein complexes at each junction. However, little is known at 
the mechanistic level about how such coordination could be accomplished. The Fung group 
proposed that Msh4-Msh5 is required at the invading end of the DSB to stabilize recombination 
intermediates such as SEIs, while Zip3 acts to promote second-end capture steps at the ligating 
end of the DSB [42]. In support of this model, the ZMM heterodimer Msh4-Msh5 has been 
shown to promote COs in the same pathway as Mlh1-Mlh3, and human MSH4-MSH5 was 
shown to bind to SEI and Holliday junction substrates in vitro [7, 40]. Furthermore, cytological 
observations in mouse have shown that MSH4-MSH5 foci appear prior to MLH1-MLH3 [37, 43-
45]. Consistent with these observations, MLH1 and MLH3 foci formation requires MSH4-MSH5 
[44].  
In this study, we created a structure-function map of Mlh3 by analyzing 60 new mlh3 
alleles in S. cerevisiae. Five alleles predicted to disrupt the Mlh1-Mlh3 endonuclease motif 
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conferred defects in both MMR and crossing over, providing further support that endonuclease 
activity is required for both functions. Importantly, we identified five mlh3 mutations that 
specifically disrupted MMR, and one mutation that specifically disrupted crossing over. By 
performing biochemical and genetic analyses of the separation of function Mlh1-mlh3 
complexes we suggest that the defects seen in our mutants can be explained by a weakening of 
protein-protein interactions, which can be tolerated in meiosis, but not MMR.  
 
Materials and Methods  
Media  
S. cerevisiae SK1, S288c, and YJM789 strains were grown on either yeast extract-
peptone- dextrose (YPD) or minimal complete media at 30 ̊C [46]. For selection purposes, 
minimal dropout media lacking uracil was used when needed. Geneticin (Invitrogen, San Diego), 
Nourseothricin (Werner BioAgents, Germany) and Hygromycin (HiMedia) were added to media 
when required at recommended concentrations [47, 48]. Cells were sporulated as described by 
Argueso et al. [7].  
 
Site-directed mutagenesis of MLH3  
60 mlh3 alleles were constructed, resulting in the mutagenesis of 139 amino acids in the 
715 amino acid Mlh3 polypeptide. The single-step integration vector (pEAI254), containing the 
SK1 MLH3 gene with a KANMX4 selectable marker inserted 40 bp downstream of the stop 
codon [8], was used as a template to create plasmids bearing the mlh3 mutant alleles via 
QuickChange site directed mutagenesis (Stratagene, La Jolla, CA). mlh3-60, in which the last 11 
residues of Pms1 (DWSSFSKDYEI) were inserted before the MLH3 stop codon, was also made 
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by QuickChange. Mutations were confirmed by sequencing the entire open reading frame 
(Sanger method), as well as 70 bp upstream and 150 bp downstream. Primer sequences used to 
make and sequence these variants are available upon request.  
 
Construction of strains to measure meiotic crossing over and MMR  
The SK1 strain EAY3255 was constructed to allow for the simultaneous analysis of mlh3 
MMR and meiotic crossing over phenotypes (Figure 3.1 and 3.2). It carries a spore autonomous 
fluorescent protein marker (RFP) on chromosome VIII to monitor chromosome behavior 
(crossing over and nondisjunction; [49]) as well as the lys2::InsE-A14 cassette to measure 
reversion to Lys
+
[50]. pEAI254 and mutant derivatives were digested with BamHI and SalI and 
introduced into EAY3255 by gene replacement using the lithium acetate transformation method 
as described in Gietz et al. [51]. At least two independent transformants for each genotype 
(verified by sequencing) were made resulting in a total of 120 haploid strains bearing the mlh3 
variants described in this study. These haploid strains were used to measure the effect of mlh3 
mutations on reversion rate and were mated to EAY3486, an mlh3Δ strain containing the CFP 
marker, resulting in diploid strains suitable for analysis of crossing over. Diploids were selected 
on media lacking the appropriate nutrients and maintained as stable strains. Meiosis was induced 
upon growing the diploid strains on sporulation media as described in Argueso et al. [7]. Wild-
type strains carrying the fluorescent protein markers used to make the above test strains were a 
gift from the Keeney lab. 
 
Lys+ reversion assays  
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The haploid strains described above were analyzed for reversion to Lys+ as described in 
Tran et al. (Figure 3.2, [50]). At least 10 independent cultures were analyzed for each mutant 
allele alongside wild-type or mlh3Δ controls. Analyses were performed for two independent 
transformants per allele. Reversion rates were measured as described [52, 53], and each median 
rate was normalized to the wild-type median rate (1X) to calculate fold increase. Alleles were 
classified into a wild-type, intermediate, or null phenotype based on the 95% confidence 
intervals which were determined as described [54].  
 
Spore autonomous fluorescent protein expression to measure percent tetratype  
Diploids in the EAY3255/EAY3486 background described above were sporulated on 
media described in Argueso et al. [7]. Spores were treated with 0.5% NP40 and briefly sonicated 
before analysis using the Zeiss AxioImager.M2 [49]. At least 250 tetrads for each mlh3 allele 
were counted to determine the % tetratype. Two independent transformants were measured per 
allele. A statistically significant difference (p<0.01) from wild-type and mlh3Δ controls based on 
χ2 analysis was used to classify each allele as exhibiting a wild-type, intermediate, or null 
phenotype.  
 
Purification of Mlh1-Mlh3 and mutant complexes from baculovirus- infected Sf9 cells  
For the results shown in Figure 3.3 and Figure 3.4, Mlh1-Mlh3 was purified using the 
following protocol: Mlh1-Mlh3 and Mlh1-mlh3 mutant derivatives were purified from Sf9 cells 
infected with Bac- to-Bac baculovirus expression system using pFastBacDual constructs [17]. 
Mutant Mlh1-mlh3 complexes were purified using the same protocol developed to purify wild-
type Mlh1-Mlh3. This involved the use of successive nickel-nitroloacetic acid-agarose [55] and 
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heparin sepharose (GE Healthcare) column purifications. Mlh1-Mlh3 and mutant derivative 
yields were ~150 μg per 5 x 108 cells; aliquots from the final heparin purification were frozen in 
liquid N2 and stored at -80 ̊C. Protein concentrations were determined by densitometry on SDS-
PAGE using BSA standard. The mlh3-6, mlh3-32 and mlh3-45 mutations were introduced into 
pEAE358 (pPH-His10-MLH3-HA pFastBacDual construct; [17]) by Quick Change (Stratagene). 
His10-mlh3-HA fragments were individually subcloned by restriction digestion into pEAE348 to 
form pFastBacDual constructs pEAE382 (Mlh1-mlh3-6), pEAE383 (Mlh1-mlh3-32) and 
pEAE384 (Mlh1-mlh3-45), in which the MLH1-FLAG gene is downstream of the p10 promoter 
and the His10 -mlh3-HA gene is downstream of the pPH promoter. The sequence of the 
restriction fragments inserted into pEAE348 were confirmed by DNA sequencing (Cornell 
Biotechnology Resource Center). Msh2-Msh3 was purified as described previously [56].  
 
Endonuclease assay on supercoiled plasmid DNA and ATPase assay  
Mlh1-Mlh3 nicking activity was assayed on supercoiled pBR322 (Thermo Scientific) 
(Figure 3.3 and 3.4). DNA (2.2 nM) was incubated in 20 μl reactions containing indicated 
amounts of Mlh1-Mlh3 and Msh2-Msh3 [56] in 20 mM HEPES-KOH pH 7.5, 20 mM KCl, 0.2 
mg/ml BSA, 1% glycerol, and 1 mM MgCl2 for 1 h at 37 ̊C. Reactions were quenched by 
incubation for 20 min at 37 ̊C with 0.1% SDS, 14 mM EDTA, and 0.1 mg/ml proteinase K (New 
England Biolabs) (final concentrations). Samples were resolved by 1% agarose gel with 0.1 
μg/ml ethidium bromide run in 1X TAE buffer for 50 min at 95 V. All quantifications were 
performed using GelEval (FrogDance Software, v1.37). The amount of nicked product was 
quantified as a fraction of the total starting substrate in independent experiments. bkg indicates 
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that amount of nicked product was not above background levels established by negative controls. 
ATPase assays were performed as described [17].  
Cloning mouse Mlh1 and Mlh3 
cDNA was synthesized from total testis RNA from wildtype C57B/6J adult males using 
the SuperScript III Reverse Transcriptase Kit from ThermoFisher. Mlh1 and Mlh3 open reading 
frames were PCR amplified from cDNA using Expand High Fidelity DNA polymerase using 
primer pairs AO3365 (5’GCTAGCAGCTGATGCATATGGCGTTTGTAGCAGGAG) and 
AO3366 (5’TACCGCATGCTATGCATTAACACCGCTCAAAGACTTTG) for Mlh1, and 
AO3367 
(5’ACGTCGACGAGCTCATATGCATCACCATCACCATCACCATCACCATCACATCAGG
TGTCTATCAGATGAC) and AO3368 
(5’CGAAAGCGGCCGCGATCATGGAGGCTCACAAGG) for His10-Mlh3. Each fragment was 
cloned into the Spe1 site of pFastBac1 (ThermoFisher) using Gibson assembly PCR (NEB) to 
create pEAE393 (Mlh1) and pEAE397 (His10-Mlh3). Constructs were verified by DNA 
sequencing with NCBI reference sequences NM_026810.2 and NM_175337.2 for Mlh1 and 
Mlh3, respectively. These constructs were then modified as follows: 
1. The MBP –TEV sequence was inserted at the N-terminus of Mlh1 in pEAE393 to create 
pEAE395.  
2. The mlh3-D1185N mutation was introduced into pEAE397 by Quick Change [57] to create 
pEAE413. 
 
Chromatography analysis of the mouse MLH1-MLH3-D1185N heterodimer from 
Baculovirus-infected Sf9 cells 
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Sf9 cells were transfected with pEAE397 (His10-Mlh3), pEAE413 (His10-Mlh3-D1185N) 
and pEAE395 (MBP-Mlh1) using the Bac-to-Bac baculovirus infection system. Fresh Sf9 cells 
were co-infected with both viruses (containing Mlh1 and Mlh3 or Mlh3-D1185N). Cells were 
harvested 60 hours post infection, washed with phosphate buffered saline, and kept at -80°C until 
use.  
Cell pellets from 250 ml of cells were thawed, resuspended in 60 ml hypotonic lysis 
buffer (20 mM HEPES-KOH pH 7.5, 5 mM NaCl, 1 mM MgCl2, 1 mM PMSF and EDTA free 
protease inhibitor mixture from Roche and Thermo Scientific) and incubated for 15 min on ice. 
The suspension was adjusted to 250 mM NaCl, 15 mM imidazole, 10% glycerol, 2 mM ß-
mercaptoethanol (BME), and clarified by centrifugation at 17,000 g for 20 min at 4°C. The 
supernatant was mixed with 6 ml of 50% nickel-nitrolotriaceticacid-agarose (Ni-NTA) resin and 
allowed to bind for 2 hours or overnight followed by centrifugation to remove the unbound 
fraction. The resin was packed onto a column and washed with 7-10 column volumes of wash 
buffer (50 mM HEPES-KOH pH 7.5, 250 mM NaCl, 40 mM imidazole, 10% glycerol, 2 mM 
BME, 1 mM PMSF). Protein was eluted with 15 ml of 300 mM imidazole in 50 mM HEPES-
KOH pH 7.5, 250 mM NaCl, 40 mM imidazole, 10% glycerol, 2 mM BME and 1 mM PMSF. 
Elution fractions containing MLH1-MLH3, determined by SDS-PAGE, were pooled and loaded 
onto 1 ml 100% amylose resin (NEB). The resin was washed with 10 column volumes of wash 
buffer (50 mM HEPES-KOH pH 7.5, 250 mM NaCl, 10% glycerol, 2 mM BME, 1 mM PMSF) 
and eluted with 6 ml wash buffer containing 10 mM maltose. Fractions containing MLH1-MLH3 
were pooled and aliquots were flash frozen and stored in -80°C. The protein yield, following 
amylose chromatography, was similar for wild-type and mutant complexes (Figure 3.5, 
approximately 120-150 µg per 250 ml cells). 
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It is important to note that we were unable to detect a specific endonuclease activity for 
the mouse MBP-MLH1-MLH3 complex, suggesting that the MBP tag interferes with MLH1-
MLH3 functions. We were unable to test this directly because, despite numerous attempts, we 
were unable to efficiently remove the MBP tag from MLH1 by treating MBP-MLH1-MLH3 
with TEV protease. 
 
Mass-spectrometry of MLH1 and MLH3 bands from SDS-PAGE 
SDS-PAGE bands following amylose chromatography predicted to contain MBP-MLH1 
and His10-MLH3 were excised and analyzed by the Cornell University Proteomics facility using 
a Thermo LTQ Orbitrap Velos Mass Spectrometer (Figure 3.5C). 
 
Results 
Rationale for site-directed mutagenesis of MLH3  
Mlh3 contains a highly conserved N-terminal ATP binding motif, a dynamic and 
unstructured motif known as the linker arm, and an endonuclease active site that overlaps with a 
C- terminal Mlh1 interaction domain [58]. We performed a clustered charged-to-alanine 
scanning mutagenesis of the S. cerevisiae MLH3 gene to create 60 mlh3 variants (Figure 3.1). 
Charged residues were considered “clustered” if there were at least two charged residues, 
consecutive or separated by at most one amino acid, within the primary sequence of Mlh3. Such 
a directed approach, in the absence of a complete crystal structure, is aimed at targeting the 
surface of a protein where clusters of charged residues likely reside, while minimizing changes 
within the interior. In this model, replacement of a charged patch from Mlh3’s surface with 
alanine residues would disrupt protein-protein or protein-DNA interactions without affecting 
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Mlh3 structure. As shown below, we identified a subset of mutations that caused strong defects 
in either MMR or crossing over, but not both, likely through disrupted interactions with Mlh1 
and other MMR and meiotic CO factors.  
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Figure 3.1 Site directed mutagenesis of MLH3. A. Functional organization of Mlh3 based on 
sequence homology and secondary structure prediction [58]. The vertical bars indicate the 
approximate position of the mlh3 mutations (except mlh3-60) analyzed in this study and 
described in panel B. mlh3-39, -40, -57, -58, and -59 colored in red are based on highly 
conserved residues in the endonuclease motifs of Pms1 which were shown in the crystal structure 
of Mlh1-Pms1 to form a single metal binding site [58]. B. Amino acid positions of charged-to-
alanine substitutions presented in red on the primary sequence of Saccharomyces cerevisiae 
Mlh3. Each cluster of underlined residues represents one allele corresponding to the vertical bars 
in panel A. mlh3-39, -40, -57, -58, and -59 are colored in red as in panel A. mlh3-60 represents 
the last 11 residues of Pms1 which constitute patch II of the heterodimerization interface of 
Mlh1-Pms1 [58].  
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Comparison of the MMR and CO assay results for each individual allele led to the 
identification of six separation of function mutations, defined as showing strong defects in one 
function (e.g. MMR) relative to another (e.g. CO), in the Mlh3 ATP-binding motifs, N-terminal 
domain beyond the ATP-binding motifs, linker arm, and the interaction domain (Figure 3.2, 
indicated by stars). One of these alleles (mlh3-32) conferred a nearly wild-type phenotype for 
MMR and a null phenotype for crossing over on chromosome VIII (hereafter referred to as 
MMR+, CO-). The remaining five mutations (mlh3-6, mlh3-23, mlh3-42, mlh3-45, and mlh3-54) 
conferred null MMR phenotypes and nearly wild-type levels of crossing over (hereafter referred 
to as MMR-, CO+). 
The phenotypes observed in the separation of function mutants may result from a defect 
in DNA binding/substrate specificity, endonuclease activity, interactions with specific MMR and 
meiotic CO factors, or changes in protein conformation. It is important to note that a co-crystal 
structure of the N-terminal domain of E. coli MutL (LN40) and E. coli MutS was recently 
solved. This work showed that conformational changes license MutS-MutL interaction and are 
essential for MMR [59, 60]. 
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Figure 3.2 Separation of function mutants of mlh3. MMR (top) and CO (bottom) phenotypes 
for MLH3 and mlh3 null (mlh3Δ), separation of function, endonuclease, and C-terminal tail 
(mlh3-60) mutants. Mismatch repair was measured using the lys2-A14 reversion assay [50][and 
crossing over was measured using the assay depicted in panel A. Bars represent the median 
reversion rates (error bars based on 95% confidence intervals) and percent tetratype normalized 
to MLH3 (1X). For mismatch repair (top), bars represent reversion rates of at least 10 
independently tested cultures from two independently constructed strains presented here 
normalized to MLH3 median rate of 1X = 1.43x10-6 (n = 140). For crossing over (bottom), bars 
represent percent tetratype of at least 250 tetrads from two independently constructed strains 
presented here normalized to MLH3 percent tetratype 1X = 36.7% (n = 226). Blue and red dotted 
lines represent MLH3 and mlh3Δ respectively. * indicate separation of function mutants. 
  
No
rm
al
ize
d
re
ve
rs
io
n 
ra
te
-1.5
-1
-0.5
0
No
rm
al
ize
d 
%
 te
tra
ty
pe
Al-Sweel et al. Fig. 3
A
0
5
10
15
20
25
30
M
LH
3
m
lh
3Δ
m
lh
3-
6
m
lh
3-
23
m
lh
3-
32
m
lh
3-
39
m
lh
3-
40
m
lh
3-
41
m
lh
3-
42
m
lh
3-
45
m
lh
3-
57
m
lh
3-
54
m
lh
3-
58
m
lh
3-
59
m
lh
3-
60
*
*
* * * *
 113 
 
Fig 3.3 Mlh1-mlh3-32 and Mlh1-mlh3-45 display wild-type endonuclease activities that are 
differentially stimulated by Msh2-Msh3. A. SDS-PAGE analysis of purified Mlh1-Mlh3, 
Mlh1-mlh3-32 and Mlh1-mlh3-45. Coomassie Blue R250-stained 8% Tris-glycine gel. 0.5 μg of 
each protein is shown. MW = Molecular Weight Standards from top to bottom- 200, 116, 97, 66, 
45 kD). B, C. Mlh1-Mlh3, Mlh1-mlh3-32 and Mlh1-mlh3-45 (18, 37, 70 nM) were incubated 
with 2.2 nM supercoiled pBR322 DNA, and analyzed in agarose gel electrophoresis (C) and the 
endonuclease activity was quantified (average of 6 independent experiments presented +/-SD) as 
described in the Methods. Ladder: 1 kb DNA ladder (New England BioLabs). Migration of 
closed circular (cc), nicked (nc) and linear (l) pBR322 DNA is indicated. D. Endonuclease 
assays were performed as in B., but contained 20 nM of the indicated wild-type or mutant Mlh1-
Mlh3 complex and 40 nM Msh2-Msh3 when indicated. Reactions were performed in triplicate, 
samples were resolved on agarose gels, and the fraction of nicked DNA was quantified, 
averaged, and the standard deviation between experiments was calculated. The average fraction 
of supercoiled substrate cleaved is presented +/-S.D. below the gel. (bkg) background, (cc) 
closed circular DNA, (nc) nicked DNA.  
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Mlh1-mlh3-32 and Mlh1-mlh3-45 display wild-type endonuclease activities but only Mlh1-
mlh3-32 endonuclease is stimulated by Msh2-Msh3  
I examined Mlh1-mlh3 mutant complexes for endonuclease activity [16, 17], focusing on 
opposite separation of function mutants Mlh1-mlh3-32 (MMR+, CO-), Mlh1-mlh3-6, and Mlh1-
mlh3-45 (MMR-, CO+). Mlh1-mlh3-45, located in the C-terminal Mlh1 interaction domain, was 
chosen because it is the only separation of function mutant in that domain that displayed wild-
type Mlh1-Mlh3 interactions as measured in the two-hybrid assay. As shown in Figure 3.3 and 
Figure 3.4, all three mutant complexes purified as heterodimers and display endonuclease 
activities similar to wild-type. When this work was initiated I thought that separation of function 
mutant complexes might show endonuclease defects indicating that this activity is more critical 
for MMR or crossing over, or show no endonuclease defects because mutant complexes were 
defective in interacting with MMR or CO specific factors. My finding that all three mutants have 
enzymatic activity comparable to wild-type is consistent with the interaction defect model (see 
below). The mlh3-6 mutation maps close to conserved sites in the ATP binding motif. I then 
tested whether the mutant complex displayed a defect in ATPase activity. As shown in Figure 
3.4, Mlh1-Mlh3 and Mlh1-mlh3-6 displayed similar ATPase activities.  
Because Mlh1-Mlh3’s endonuclease activity is enhanced by Msh2-Msh3 [17], I tested 
whether the opposite separation of function phenotypes of Mlh1-mlh3-32 and Mlh1-mlh3-45 
could be explained by defective interactions with MSH complexes. As shown in Figure 3.3, 
Mlh1-mlh3-32 endonuclease activity but not Mlh1-mlh3-45 could be stimulated by Msh2-Msh3. 
These data are consistent with the MMR-, CO+ phenotype exhibited by mlh3-45 mutants 
resulting from a defect in interacting with the MMR component Msh2-Msh3, and the mlh3-32 
mutant likely being defective in interactions with meiosis-specific factors.  
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Figure 3.4: Mlh1-mlh3-6 exhibits wild-type endonuclease and ATPase activity. 
A. SDS-PAGE analysis of purified Mlh1-Mlh3 and Mlh1-mlh3-6. Coomassie Blue R250-stained 
8% Tris-glycine gel. 0.5 μg of each protein is shown. MW = Molecular Weight Standards from 
top to bottom-116, 97, 66, 45, 31 kD). B, C. Mlh1-Mlh3 and Mlh1-mlh3-6 (18, 37, 70 nM) were 
incubated with 2.2 nM supercoiled pBR322 DNA, analyzed in agarose gel electrophoresis, and 
endonuclease activity was quantified (average of 6 independent experiments presented +/-SD) as 
described in the Methods. C. ATPase assays were performed as described in Rogacheva et al. 
[17], but contained the indicated amounts of Mlh1-Mlh3 and Mlh1-mlh3-6 incubated with 100 
μM 32P-γ-ATP. Reactions were performed in duplicate for two separate purifications of each, and 
the average values, +/-SD, are presented 
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Cloning and analysis of the mouse MLH1-MLH3 complex 
To determine if the yeast and mouse Mlh1-Mlh3 complexes displayed similar activities, I 
developed methods to overexpress and purify mouse MLH1-MLH3. Mouse Mlh1 and Mlh3 were 
amplified from cDNA and cloned into pFastBac1 vectors as described in the Methods. The 
MLH1-MLH3 and MLH1-MLH3-D1185N complexes were expressed from Sf9 cells infected 
with baculoviruses containing MBP-Mlh1 and His10-Mlh3 or His10-Mlh3-D1185N constructs 
(Figure 3.5A). Extracts from these cells were applied to a Ni-NTA column. Fractions containing 
induced proteins were pooled and then applied to an amylose column. Two major bands of 
molecular weights predicted for an MBP-MLH1-His10-MLH3 complex were detected on SDS-
PAGE after amylose chromatography (Figure 3.5B). These bands were further analyzed by mass 
spectrometry, and the results from this analysis confirmed their identity (Figure 3.5C). 
Importantly, MLH1-MLH3 and MLH1-MLH3-D1185N eluted with an apparent 1:1 
stoichiometry in both chromatography steps, indicating that the heterodimers were stable, and the 
protein yields of the two complexes after amylose chromatography were similar (Figure 3.5B). 
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Figure 3.5: Mouse MLH3-D1185N forms a stable complex with MLH1. A) Schematic of 
mouse Mlh1 and Mlh3 constructs (see Methods for details). (B) Representative purification of 
MBP-MLH1-MLH3 (top) and MBP-MLH1-mlh3-D1185N (bottom) using Ni-NTA and amylose 
resin chromatography as described in the Methods. Fractions were analyzed using SDS- PAGE, 
stained by Coomassie brilliant blue. MLH1-MLH3 and MLH1-MLH3-D1185N were eluted from 
amylose in the same fractions. The mass of molecular weight standards is indicated on the left 
and the expected positions of MBP-MLH1 (127.5 KDa) and His10-MLH3 (165 KDa) is 
indicated in the center. *Likely to be degradation products of MLH1-MLH3. (C) Mass 
spectrometry analysis of the two major bands in SDS-PAGE detected after amylose 
chromatography.  
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Discussion  
We performed a structure-function analysis of Mlh3, a factor that acts in both MMR and 
meiotic crossing over. This work was pursued because little is known about how Mlh1-Mlh3 acts 
as a meiotic endonuclease. This is due in part to Mlh1-Mlh3 sharing little in common with the 
well-characterized structure-selective endonucleases (SSNs are structure selective endonucleases 
that recognize and cleave dHJs or other such structures specifically; Mus81-Mms4, Slx1-Slx4, 
and Yen1) in terms of homology and intrinsic behavior in vitro (reviewed in [29]). Obtaining 
new mechanistic insights has been complicated by the fact that Mlh1-Mlh3 can bind to model HJ 
substrates, but cannot cleave them, and by genetic studies suggesting that Mlh1-Mlh3 acts in 
concert with other pro-CO factors [16, 17, 29, 61]. Recent work has suggested that multiple 
Mlh1-Mlh3 heterodimers are required to activate the endonuclease and that the complex is at 
least partially inhibited by incorporation of a DNA secondary structure that is not part of a 
continuous homoduplex substrate [61]. These data suggest that other protein factors likely recruit 
and position Mlh1-Mlh3 complexes during meiotic recombination. The identities of these factors 
are for the most part known, though it is not understood how they directly contribute to Mlh1-
Mlh3’s ability to nick DNA in the directed manner required to generate COs.  
Our analysis of mlh3-32 (MMR+, CO-) and mlh3-45 (MMR-, CO+), support the above 
hypothesis that protein-protein interactions are critical for directing Mlh1-Mlh3 endonuclease 
activity (Figure 3.3). Mlh1-Mlh3 has been shown genetically to act downstream of Msh4-Msh5 
[37-39, 43]; this order of events is analogous to steps in DNA MMR where MLH acts following 
MSH recognition [62, 63]. As outlined in the introduction, Msh4-Msh5, STR, Exo1 (independent 
of its enzymatic activity) and Zip3 have been classified as pro-CO factors, and have all been 
shown to interact with one another and/or with Mlh1-Mlh3 (reviewed in [29]). Our biochemical 
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studies are consistent with Mlh1-mlh3-45 having interaction defects that prevent its 
endonuclease activity from being stimulated by Msh2-Msh3 in MMR. We hypothesize that MLH 
complexes interact with MSH complexes via a common mechanism, and that defective 
interactions with Msh2-Msh3 are also indicative of defective interactions with Msh4-Msh5, but 
during meiotic CO resolution, additional factors such as Exo1, Sgs1-Top3-Rmi1 and Zip3 act in 
concert to strengthen a possibly weakened Msh4-Msh5 and Mlh1-mlh3-45 interaction. This 
model also helps explain why we identified several MMR- CO+ mlh3 mutants (mlh3-42 and -54) 
in which the mutant mlh3 protein fails to interact with Mlh1. For the Mlh1-mlh3-32 complex, the 
MSH interaction and enhancement is retained, but interaction with other critical meiotic factors 
is likely lost, possibly resulting in an unstable complex that cannot resolve dHJs.   
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Appendix A 
A new protocol for purifying the yeast Mlh1-Mlh3 complex. 
 
Introduction and Results 
A year after the work published in Al-Sweel et al [1], we noticed in newer preparations 
that there was a contaminating endonuclease activity copurifying with Mlh1-mlh3-DN using our 
standard protocol. Carol Manhart in our lab has shown multiple times using this protocol that 
endonuclease dead protein could be purified without any nuclease contamination, but something 
had changed in the reagents or cells of our newer preparations that we were unable to track 
down. Because of this issue, I developed a new protocol written in detail below to purify yeast 
Mlh1-Mlh3 and endonuclease dead mutant and demonstrated that the wild type was active and 
the endonuclease dead version was inactive, indicating that the purification was free of 
contaminating endonucleases (Figure 3.6). The new protocol for purification of the Mlh1-Mlh3 
complex involved affinity chromatography with anti-FLAG resin, followed by affinity 
chromatography with Ni-NTA and dialysis. Mlh1-Mlh3 and endonuclease active site mutant 
Mlh1-mlh3-DN were purified as heterodimers with 1:1 stoichiometry of Mlh1 and Mlh3 or 
mlh3-DN (Figure 3.6 A). The protein yields were greatly increased using this method (1mg 
versus 150µg per 5 x 108 cells). The wild type was endonuclease active with the highest activity 
seen with 5mM MnSO4 (Figure 3.6 B, C). Lower amounts of endonuclease activity were 
observed with 1mM MnSO4, 5mM MgCl2 and 1mM MgCl2 in this order (Figure 3.6 B). The 
endonuclease active site mutant Mlh1-mlh3-DN only had a low endonuclease activity at very 
high protein concentration of 300nM and did not show any endonuclease activity above 
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background otherwise (Figure 3.6 B, C). Moreover, similar to the older established preparation, 
using the new protocol for purification, I observed similar preference for larger sized plasmid 
substrate as seen before.  
Materials and Methods 
 
Purification of yeast Mlh1-Mlh3 
Mlh1-Mlh3 and Mlh1-mlh3-DN were expressed in Sf9 cells as described above. The 
pellets, each containing 300ml cells were frozen as pellets in -80ºC. The purification was divided 
into four parts:  
A. Cell lysis  
B. Affinity purification using the FLAG resin  
C. Affinity purification using the NiNTA resin 
D. Dialysis to remove Imidazole. 
 
1. The cell pellet containing 300ml cells was thawed on ice in the cold room for 1 hour. It 
was resuspended in 15 mL hypotonic lysis buffer (20mM HEPES-KOH, pH7.5, 5mM 
KCl, 1mM MgCl2, 0.5% Tween-20, 1mM PMSF, 1X Halt protease inhibitor cocktail 
EDTA-free (Thermo), 1 tablet complete protease inhibitor tablet EDTA-free [64]), in the 
cold room. The lysate was incubated on ice for 20 min.  
2. The suspension was adjusted to have final concentrations of the components as follows: 
100mM KCl, 400mM NaCl, 1mM 2-mercaptoethanol, 10% glycerol. The lysate was 
centrifuged at 17,000xg for 20 min at 4ºC.  
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3. The supernatant was applied over 1.5 ml of 50% M2 anti-FLAG agarose beads (Sigma-
Aldrich), pre-equilibrated in FLAG equilibration buffer (25mM HEPES-KOH, pH 7.5, 
100mM KCl, 400mM NaCl, 1mM EDTA, 10% Glycerol, 0.2% Tween-20, 1.4mM 2-
mercaptoethanol, 1mM PMSF) and incubated with rotation for 1 hour.  
4. The column was washed with 25 column volumes of FLAG wash buffer (25mM HEPES-
KOH, pH 7.5, 100mM KCl, 400mM NaCl, 10% glycerol, 02% Tween-20, 1.4mM 2-
mercaptoethanol, 1mM PMSF) and 0.5ml fractions were eluted using FLAG elution 
buffer (6ml FLAG wash buffer + 1500µg 3x-FLAG peptide (SIGMA)).  
5. Fractions containing Mlh1-Mlh3, determined by SDS-PAGE were pooled, imidazole was 
added to a concentration of 15mM. The protein was loaded over 3ml of 50% Ni-NTA 
agarose beads [55], pre-equilibrated in Ni-NTA binding buffer (25mM HEPES-KOH, pH 
7.5, 100mM KCl, 400mM NaCl, 15mM Imidazole, 10% Glycerol, 0.5% Tween-20, 
1.4mM 2-mercaptoethanol, 1mM PMSF) and incubated with rotation overnight at 4ºC. 
6. The column was washed with 10 column volumes of Ni-NTA wash buffer (25mM 
HEPES-KOH, pH 7.5, 100mM KCl, 300mM NaCl, 40mM Imidazole, 10% Glycerol, 
0.2% Tween-20, 1.4mM 2-mercaptoethanol, 1mM PMSF) and eluted with 8 ml Ni-NTA 
elution buffer (25mM HEPES-KOH pH 7.5, 100mM KCl, 250mM NaCl, 300mM 
Imidazole, 10% Glycerol, 02% Tween-20, 1.4mM 2-mercaptoethanol, 1mM PMSF) and 
~0.62 mL fractions were collected.  
7. Fractions containing Mlh1-Mlh3 were pooled and dialyzed for 4 hours using a 20 KDa 
cut-off Slide-A-Lyzer (Thermo-Fisher Scientific) in 1L dialysis buffer. The dialysis 
buffer was changed after the first 2 hours. Aliquots were frozen in liquid-N2, followed by 
storage at -80ºC.
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Protein concentrations were estimated by densitometry on SDS-PAGE, by running BSA 
(80-500ng per lane) and 2, 5 and 10µl pure protein in the same gel. Two such gels were run 
simultaneously to reduce error. The typical yields for both wild-type and endonuclease mutant 
derivative was ~1.2mg per 6 x 108 cells. 
Endonuclease assay 
For the Mlh1-Mlh3 purified using the new protocol, shown in Figure 3.6 the same 
endonuclease assay method as in Chapter 3 was used with the following exceptions: 5mM 
MnSO4 or 5mM MgCl2 were used in place of 1mM MgCl2. 
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Figure 3.6: Mlh1-Mlh3 purified using a new protocol involving FLAG and Ni-NTA affinity 
chromatography is an active endonuclease, and Mlh1-mlh3-DN is inactive. A. SDS-PAGE 
analysis of purified Mlh1-Mlh3 and Mlh1-mlh3-DN. Coomassie Blue R250-stained 8% Tris-
glycine gel. 0.5 μg of each protein is shown. MW = Molecular Weight Standards from top to 
bottom- 200, 116, 97, 66, 45 kD). B Mlh1-Mlh3, Mlh1-mlh3-DN (50 and 150 nM) were 
incubated with 2.2 nM supercoiled pBR322 DNA, and either 5mM MnSO4/ 5mM MgCl2/ 1mM 
MnSO4/ 1mM MgCl2 and analyzed in agarose gel electrophoresis. Fraction of nicked DNA is 
quantified and shown. D. Endonuclease assays were performed as in B., but contained a titration 
of the wild-type Mlh1-Mlh3 or Mlh1-mlh3-DN complex (5, 20, 60, 100, 300nM) with 5mM 
MnSO4. Fraction of nicked DNA is quantified and shown. Bck is background nicking, WT is 
wild-type Mlh1-Mlh3, DN is Mlh1-mlh3-DN.  
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CHAPTER 4 
 
 
Future directions: An analysis of the role of Exo1 in meiotic crossing over 
 
 
In this chapter, I suggest future directions for the Mlh1-Mlh3 meiosis work described in Chapter 
3. The future directions for the Mlh1-Pms1 incompatibility work with clinical isolates is written 
as a part of Chapter 1. 
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Introduction 
The crossover resolution step involves ZMM proteins Zip1-4, Mer3, and Msh4-Msh5 as 
well as the Sgs1-Top3-Rmi1 (STR) helicase/topoisomerase complex, Mlh1-Mlh3, and Exo1. 
Biochemical analyses of Mlh1-Mlh3 protein complex indicate that it does not function as a 
structure specific nuclease to nick Holliday junctions and that Mlh1-Mlh3 is being directed by 
other protein complexes to nick a dHJ. Hence, it is important to study Mlh1-Mlh3 in the context 
of other recombination proteins such as Msh4-Msh5, Exo1, Sgs1, Top3, Rmi1, as also to develop 
substrates that will resemble the in-vivo Holliday junction more accurately. Towards this goal I 
started to tease apart the role of Exo1 in recombination, and to understand how it interacts with 
Mlh1-Mlh3 to resolve dHJs.  
Exo1 is a nuclease of Rad2/XPG family and has both 5’-3’ exonuclease as well as 5’ flap 
endonuclease activities [1]. Interestingly, Exo1 is thought to have a structural or a non-catalytic 
role in resolving crossovers and data from the Hunter and Borts laboratory suggests that the 
nuclease function of Exo1 is not necessary for crossing over [2, 3]. But it is not completely 
understood how it interacts with Mlh1-Mlh3 and whether it has any role in directing Mlh1-Mlh3 
to nick at the double Holliday junction to generate crossover products. 
My hypothesis is that Exo1 acts as a scaffold at the crossover resolution step, interacting 
with multiple protein factors such as Mlh1-Mlh3, Sgs1, with which it is known to interact as well 
as mediating interactions with other factors such as Zip3, Msh4-Msh5. Exo1 in addition to 
Msh4-Msh5 may be recruiting and directing Mlh1-Mlh3 to create the nicks in an asymmetric 
manner at the dHJ site to facilitate crossover resolution. Hence, I wanted to test if Exo1 can 
stimulate the enzymatic activity of Mlh1-Mlh3 in-vitro. To do this we need an Exo1 that is 
nuclease deficient, to eliminate its contribution as a nuclease and focus on its structural function. 
 134 
Others in the Alani laboratory observed that Exo-D173A, the nuclease active site mutant 
reported in the literature had residual endonuclease activity in vitro. So, I set out to identify a 
mutant that was active in crossing over but inactive as a nuclease. Towards this goal, I generated 
a system to study the crossover phenotype in exo1 mutants as described below. 
Materials and Methods 
Cloning yeast EXO1 
HiFi DNA Assembly (NEB) was used to construct EXO1 (pEAI423) and exo1' 
(pEAI422) constructs (Figure 4.1). EXO1 was PCR amplified from genomic DNA isolated from 
SKY3576 (SK1 strain) using AO4030 
(gcatgcctgcaggtcgactctagagGCGTCTTTAGCAAAGGCG) and AO4031 
(gggcctccatgtcTAGCGGCTTGATTAGATAAATAGAG), KANMX was PCR amplified from 
pFA6 plasmid using AO4032 (aatcaagccgctaGACATGGAGGCCCAGAATAC) and AO 4033 
(gaatgtagaccgcCAGTATAGCGACCAGCATTC), downstream region of EXO1 was PCR 
amplified from genomic DNA using AO4034 (ggtcgctatactgGCGGTCTACATTCGCTATC) and 
AO4035 (tacgaattcgagctcggtacccgggGGCATAAGAAGGCACGTC). The three inserts were 
cloned into pUC18 plasmid linearized with BamH1. 
To construct pEAI422 (exo1'), KANMX was amplified from pFA6 plasmid using 
AO4037 (tcttcctcagttaGACATGGAGGCCCAGAATAC) and AO4038 
(attgggaaagcaaCAGTATAGCGACCAGCATTC), EXO1 5’ flanking region (280bp) PCR 
amplified from SK1 genomic DNA using AO4030 and AO4036 
(gggcctccatgtcTAACTGAGGAAGAAGACCTTG), EXO1 3’ flank (340bp) PCR amplified from 
SK1 genomic DNA using AO4039 (ggtcgctatactgTTGCTTTCCCAATTTGTTTATAAAG) and 
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AO4040 (tacgaattcgagctcggtacccgggGGAAAAAAAAATGTGAATTGC). The three inserts 
were cloned into pUC18 linearized with BamH1. 
pEAI424-427, pEAI436, pEAI437 were constructed with Q5 mutagenesis kit (NEB) using 
pEAI423 as template. 
Mutational analysis of Exo1 
pEAI423 and mutant derivatives (generated by Q5 mutagenesis kit-NEB) were digested 
with Spe1 and Nhe1 and the null strain was generated by digesting pEAI422 with Spe1 and Sma1 
and they were all introduced into SKY3576 and SKY3575 by gene replacement using the lithium 
acetate transformation method as described in Gietz et al. [4]. At least two independent 
transformants for each genotype (verified by sequencing) were made resulting in a total of 39 
haploid strains bearing either the exo1 variants, wild type or null. The haploid of each variant in 
SKY3576 was mated with the haploid of the same variant in SK3575 and the diploid was 
selected on media lacking leucine and tryptophan and maintained as stable strains. Meiosis was 
induced upon growing the diploid strains on sporulation media as described in Argueso et al. [5]. 
Wild-type strains carrying the fluorescent protein markers used to make the above test strains 
were a gift from the Keeney lab. Strains and plasmids used in this work are shown in Table 4.1, 
Table 4.2 and Figure 4.1. 
 
Exo1 homology model 
The amino acid sequence of yeast Exo1 (amino acids 2-356) was used to construct a 
homology model (Figure 4.2) using the Phyre2 software 
(http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index). This predicted structure was then 
aligned to human Exo1 (PDB ID: 3QEB) using Pymol (https://pymol.org/2/). 
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Spore autonomous fluorescent protein expression to measure percent tetratype  
Diploids in the SKY3576 (MATa; ho::LYS2; lys2; ura3; leu2::hisG; trp1::hisG; 
THR1::m‐Cerulean‐TRP1) /SKY3575(MATα; ho::LYS2; lys2; ura3; leu2::hisG; trp1::hisG; 
CEN8::tdTomato‐LEU2) background described above were sporulated on media described in 
Argueso et al. [5]. Spores were treated with 0.5% NP40 and briefly sonicated before analysis 
using the Zeiss AxioImager.M2 [6]. At least 500 tetrads for each exo1 allele were counted to 
determine the % tetratype. Two independent transformants were measured per allele (Table 4.3). 
A statistically significant difference (p<0.01) from wild-type and mlh3Δ controls based on χ2 
analysis was used to classify each allele as exhibiting a wild-type, intermediate, or null 
phenotype.  
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Table 4.1: Yeast strains used to study exo1 mutants 
 
Strain Genotype in the SK1 strain background 
EAY4154-4156 MATa; ho::LYS2; lys2; ura3; leu2::hisG; trp1::hisG; THR1::m‐Cerulean‐
TRP1, EXO1::KANMX 
EAY4157-4159 MATα; ho::LYS2; lys2; ura3; leu2::hisG; trp1::hisG; CEN8::tdTomato‐
LEU2, EXO1::KANMX 
EAY4149-4150 MATa; ho::LYS2; lys2; ura3; leu2::hisG; trp1::hisG; THR1::m‐Cerulean‐
TRP1, exo1Δ::KANMX 
EAY4151-4153 MATα; ho::LYS2; lys2; ura3; leu2::hisG; trp1::hisG; CEN8::tdTomato‐
LEU2, exo1Δ::KANMX 
  Amino acid substitution 
EAY4160-4162 Same as EAY4154, but exo1- D78A::KANMX D78A 
EAY4163-4164 Same as EAY4157, but exo1- D78A::KANMX D78A 
EAY4165-4167 Same as EAY4154, but exo1- D173A::KANMX D173A 
EAY4168-4170 Same as EAY4157, but exo1- D173A::KANMX D173A 
EAY4171-4172 Same as EAY4154, but exo1- G236D::KANMX G236D 
EAY4173-4174 Same as EAY4157, but exo1- G236D::KANMX G236D 
EAY4175-4177 Same as EAY4154, but exo1- D78A, 
D173A::KANMX 
D78A, D173A 
EAY4178 Same as EAY4157, but exo1- D78A, 
D173A::KANMX 
D78A, D173A 
EAY4179 Same as EAY4154, but exo1- G236D, 
D173A::KANMX 
G236D, D173A 
EAY4180-4181 Same as EAY4157, but exo1- G236D, 
D173A::KANMX 
G236D, D173A 
EAY4182-4184 Same as EAY4154, but exo1- F447A, 
F448A::KANMX 
F447A, F448A (MIP) 
EAY4185-4187 Same as EAY4157, but exo1- F447A, 
F448A::KANMX 
F447A, F448A (MIP) 
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 Table 4.2: Plasmids containing EXO1 and exo1 alleles 
 
Plasmid Allele 
pEAI423 EXO1::KANMX 
pEAI422 exo1Δ::KANMX 
pEAI424 exo1-D78A::KANMX 
pEAI425 exo1-D173A::KANMX 
pEAI426 exo1-G236D::KANMX 
pEAI427 exo1- D78A, D173A::KANMX 
pEAI436 exo1- G236D, D173A::KANMX 
pEAI437 exo1- F447A, F448A::KANMX 
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Figure 4.1: EXO1 Plasmid maps. A. Construct containing wild-type EXO1::KANMX or 
pEAI423. pEAI424-427 and pEAI436, pEAI437 were constructed by Q5 mutagenesis of 
pEAI423 using appropriate primers. B. Construct containing upstream and downstream 
sequences of EXO1 interrupted by a KANMX sequence for making exo1' yeast strains by 
integration.   
A
B
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Figure 4.2: Yeast Exo1 modelled on a DNA substrate based on sequence homology to 
human Exo1. The amino acids predicted to be involved in DNA binding: G236, and the active 
site: D173, D78, D152, D171 and other charged residues in the vicinity of the active site: D225, 
D30 are shown. M1 and M2 are the metals at the active site that aid in the catalytic activity of 
this enzyme. 
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Results 
I generated a system to study the crossover phenotype in exo1 mutants using the Keeney 
laboratory’s spore autonomous fluorescent assay (Table 4.1, 4.2). I compared EXO1, exo1Δ, 
exo1-F447A, 448A exo1-D78A, exo1-D173A, exo1-D78A, D173A, exo1-G236D and exo1-
G236D, D173A. The crossing over phenotypes for the wild type and null were as expected and 
the exo1-F447A, F448A mutant, mutated in the  Mlh1 interaction domain (MIP domain), had an 
intermediate phenotype, as observed previously (Table 4.3, [3]). The mutants selected to disrupt 
the nuclease active site: D78A, D173A and the double mutant, were also functional in crossing 
over (Table 4.3). These results further support the idea that Exo1 has a structural role in 
crossover resolution. The predicted DNA binding mutant, exo1-G236D has an intermediate 
phenotype (Table 4.3). Interestingly the double mutant of exo1-G236D, D173A was wild-type, 
indicating that the DNA binding mutant may have some non-specific interactions with DNA, but 
removal of the exonuclease function by D173A mutation in this background, brings it back to 
wild type levels (Table 4.3). This system allows us to test more mutants of Exo1 to further 
understand its role in crossing over (Table 4.4).  
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Table 4.3: Crossover (CO) phenotypes of the exo1 variants as measured in spore 
autonomous fluorescent assays.  
Two independently constructed strains with exo1 variants in the EAY3339 (containing cyan 
fluorescent protein) and EAY3341 (containing red fluorescent protein) background were 
analyzed. For each variant, at least two independent transformants were analyzed for each 
background. The variant in the EAY3339 background was crossed with the variant in the 
EAY3341 background so that each mutation was homozygous. Diploid strains were induced for 
meiosis and % tetratype was measured. At least 500 tetrads were counted for each allele. WT is 
wild-type. +, indistinguishable from WT as measured by χ2 (p<0.01, for % tetratype). -, 
indistinguishable from null as measured by χ2 (p<0.01). INT is intermediate, distinguishable 
from both wild-type and null as measured by χ2 (p<0.01).  
  
Strain % Tetratype Number 
of tetrads 
counted 
CO 
phenotype 
EXO1-KANMX x EXO1-KANMX 37.5 550 + 
exo1Δ x exo1Δ 22.0 549 - 
exo1-D78A x exo1-D78A 39.7 531 + 
exo1-D173A x exo1-D173A 37.4 519 + 
exo1-D78A, D173A x exo1-D78A, D173A 36.4 544 + 
exo1-G236D x exo1-G236D 29.9 521 INT 
exo1-G236D, D173A x exo1-G236D, D173A 35.7 532 + 
exo1-F447A, F448A x exo1-F447A, F448A 31.1 547 INT 
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Open questions and future plans 
How Exo1 functions in crossing over and how it coordinates with Mlh1-Mlh3 complex 
remains a mystery. A targeted mutation strategy to identify DNA binding residues and catalytic 
domain of Exo1 would further the understanding of the requirements of Exo1 in its crossing over 
role. It will also aid in identification of mutants of Exo1 that can be used biochemically to test 
the combined action of Exo1 and Mlh1-Mlh3. I have compiled a list of residues in Exo1 that can 
be mutated to disrupt the DNA binding (based on human EXO1 data Orans, J. et al [7]) or 
catalytic activities (based on homology model Figure 4.2) as well as a combined mutation in the 
Mlh1-interaction domain and a DNA binding mutant (Table 4.4). We still need to understand if 
DNA binding by Exo1 is required for its role in crossing over. My hypothesis for the 
intermediate phenotype of the DNA binding mutant exo1-G236D (Table 4.3) is that it interacts 
with DNA non-specifically initiating nuclease cleavage at undesired sites. Mutating other DNA 
binding residues will help identify residues that may obliterate DNA-binding and some that may 
result in non-specific binding. One could test a combination of different DNA binding mutants 
with the catalytic D173A mutation to see if non-specific binding is indeed destructive to the 
function of Exo1 in crossing over, as well as testing to see if phenotype of a completely DNA 
binding deficient mutant would not change in combination with D173A. Additionally, it would 
be useful to test a combined mutation of the DNA binding residues and Mlh1- interaction 
domain residues. If DNA binding of Exo1 is not necessary for crossing over, the combined 
mutant of exo1-DNA binding and exo1-MIP should not be worse than the exo1-MIP 
(intermediate in crossing over phenotype). 
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Table 4.4: Suggested exo1 mutations to disrupt catalytic activity and DNA binding of Exo1. 
 
Catalytic DNA-binding 
D171A K61A/D 
D171A+D173A R92A/E 
K85A R96A/E 
E150A K185A/D 
D152A G234A/D 
 L235A 
 FF447,448AA + G236D 
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Identification of more catalytic residues of Exo1 that do not disrupt the crossing over 
function will allow purification of these mutant proteins to verify their lack of nuclease activity. 
The goal would be to test their interaction with Mlh1-Mlh3 as well as stimulation of the 
endonuclease activity of Mlh1-Mlh3 on plasmid substrates. Additionally, it would be interesting 
to test the nicking of Holliday junction-like structures using a combination of Mlh1-Mlh3 and 
Exo1 mutants to see if Mlh1-Mlh3 can now be directed to nick a Holliday junction [8, 9]. 
Lastly, Exo1 may be playing an important role in interacting with multiple protein 
complexes involved in resolving dHJs. Disrupting interactions with other proteins, such as Sgs1, 
similar to disrupting interaction with Mlh1, may affect the crossing over function of Exo1. An 
alanine scanning mutagenesis of charged residues on Exo1 (the strategy used for mlh3 
mutagenesis in Chapter 3, [10]) to pin-point amino acid residues that are crucial for function may 
help in identifying regions of the Exo1 that are important in interactions with other protein 
complexes. This mutagenesis may be useful to prove the ‘supercomplex hypothesis’ for 
crossover resolution in which we think that multiple protein factors including Mlh1-Mlh3, Sgs1-
Top3-Rmi1, Exo1, Zip3, Msh4-Msh5 are stabilize on the double Holliday junction by protein-
protein interactions. In this model disrupting interaction with one factor may not affect crossing 
over since interaction with other factors may compensate for the lack of one interaction. It would 
be interesting to test an Exo1 mutant that is mildly defective in crossing over, together with mlh3 
mutants: mlh3-42 or mlh3-54 (identified in Al-Sweel et al [10] as not being able to interact with 
Mlh1, but maintains crossing over function), to see if it worsens the phenotype or behaves like 
null since more parts of the supercomplex are now affected. 
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